

SUPPLEMENTARY ONLINE MATERIALS

Paper: Understanding complex dynamics of behavioral, neurochemical and transcriptomic changes induced by prolonged chronic unpredictable stress in zebrafish

Konstantin A. Demin*^{1,2}, Anton M. Lakstygala², Nataliya A. Krotova^{1,2}, Alexey Masharsky³, Natsuki Tagawa⁴, Maria V. Chernysh², Nikita P. Ilyin², Alexander S. Taranov², David S. Galstyan^{2,5}, Ksenia A. Nikolaeva¹, Nataliia A. Levchenko², Tatiana O. Kolesnikova², Mikael S. Mor², Marina L. Vasyutina¹, Evgeniya V. Efimova², Nataliia Katolikova^{2,7}, Andrey D. Prjibelski⁸, Raul R. Gainetdinov², Murilo S. de Abreu⁹, Tamara G. Amstislavskaya^{10,11}, Tatyana Strekalova¹² and Allan V. Kalueff*^{6,13}

¹Institute of Experimental Medicine, Almazov National Medical Research Centre, Ministry of Healthcare of Russian Federation, St. Petersburg, Russia

²Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia

³Core Facility Centre for Molecular and Cell Technologies, St. Petersburg State University

⁴Department of Biophysics and Biochemistry, Graduate School of Science, University of Tokyo, Tokyo, Japan

⁵Laboratory of Preclinical Bioscreening, Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russian Federation, Pesochny, Russia

⁶School of Pharmacy, Southwest University, Chongqing, China;

⁷Institute of Cytology RAS, Saint-Petersburg, Russia

⁸Center for Algorithmic Biotechnology, Institute of Translational Biomedicine, St. Petersburg State University

⁹University of Passo Fundo, Passo Fundo, Brazil

¹⁰Laboratory of Biopsychiatry, Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia

¹¹School of Medicine and Psychology, Novosibirsk State University, Novosibirsk, Russia

¹²University of Maastricht, Maastricht, Netherlands

¹³ Ural Federal University, Ekaterinburg, Russia

***Co-corresponding authors:**

Allan V. Kalueff, Ph.D., School of Pharmacy, Southwest University, Chongqing, China.


Tel/Fax: +1-240-899-9571 E-mail: avkalueff@gmail.com

Konstantin A. Demin, Institute of Translational Biomedicine SPBU, University Emb. 7-9, St. Petersburg, Russia. E-mail: deminkasci@gmail.com


Data availability

The datasets generated and/or analyzed in the present study are available from the original article, supplementary materials, or the corresponding author (upon reasonable requests, for use in collaborative research projects and/or for joint publications resulting from such projects).


Supplementary Figure S1. The MA-plots (Bland–Altman plots) of the estimated fold change over average expression strength, representing whole-brain gene expression changes induced in adult zebrafish by a 5-week chronic unpredictable stress (CUS), assessed by RNA-sequencing (n=6). Data was normalized using the rlog function¹. Graphs were constructed using the ggplot2 R package². Color dots denote genes with statistically significantly altered expression: Up – significantly up-regulated genes, down – significantly down-regulated genes, NS – no significant differences.




Supplementary Figure S2. The MA-plots (Bland–Altman plots) of the estimated fold change over average expression strength, representing whole-brain gene expression alterations induced by in adult zebrafish by a 5-week chronic unpredictable stress (CUS, as in Supplementary Figure S1) and chronic 0.1 mg/L fluoxetine treatment during the week 5 of CUS, assessed by RNA-sequencing (n=6-7). Data was normalized using the rlog function¹. Graphs were constructed using the ggplot2 R package². Color dots denote genes with statistically significantly altered expression: Up – significantly up-regulated genes, down – significantly down-regulated genes, NS – no significant differences.




Supplementary Figure S3. The MA-plots (Bland–Altman plots) of the estimated fold change over average expression strength representing whole-brain gene expression changes induced in adult zebrafish subjected to a 5-week chronic unpredictable stress (CUS) with and without chronic 0.1 mg/L fluoxetine treatment during the last CUS week, assessed by RNA-sequencing (n=6-7). Data was normalized using the rlog function¹. Graphs were constructed using the ggplot2 R package². Color dots denote genes with statistically significantly altered expression: Up – significantly up-regulated genes, down – significantly down-regulated genes, NS – no significant differences.



Supplementary Figure S4. Power graph analysis (PGA) of String PPI network. PGA is a novel method of analysis and representations of complex networks in which usual nodes and edges are replaced with power nodes and power edges constructed from common topological structures – cliques (set of nodes with an edge between each pair; represented as a loop), bicliques (two sets of nodes with edge between every member of other set; represented as two power nodes connected with power edge) and stars (set of nodes connected to single node; represented as power node connected to usual node)³.



Supplementary Figure S5. Power graph analysis (PGA) of Genemania network. PGA is a novel method of analysis and representations of complex networks in which usual nodes and edges are replaced with power nodes and power edges constructed from common topological structures – cliques (set of nodes with an edge between each pair; represented as a loop), bicliques (two sets of nodes with edge between every member of other set; represented as two power nodes connected with power edge) and stars (set of nodes connected to single node; represented as power node connected to usual node)³.



Supplementary Table S1. List of primers used in the study

| Gene name | | Primer sequence |
|---------------|---|--------------------------|
| <i>b-act</i> | F | CATCAGGGTGTCATGGTTGGT |
| | R | TCTCTTGCTCTGAGCCTCATCA |
| <i>isg 15</i> | F | ACTTGATTTCCGGTGCGACTTGC |
| | R | GCTGCATCGTCACCGAGTTAT |
| <i>otx5</i> | F | CGCCGTCGGTTACCCTAACAC |
| | R | GGTTTTGGAGAACAGCGCCT |
| <i>saga</i> | F | GTAGATCCAGTGGACGGTGTC |
| | R | GTCGTCATCACGGCCATAACC |
| <i>tpm4b</i> | F | TCGCGTTTGGCATGATGTCTG |
| | R | CTGCTACATCTCCTTCAGCTTTCT |

Supplementary Table S2. Results of Generalized Linear Model (GZLM) fits using week, group and their interaction effects as ‘predictors’, to compare stress and control group at weeks 1-5. The corrected Akaike information criterion (AICc) was used to choose the ‘best fit’ model among Gaussian distribution (identity link), Poisson distribution (with log link), Gamma distribution (inverse and log links) and Inverse Gaussian distribution (with inverse and log links) for the novel tank test (NTT), light-dark test (LDT), shoaling test (ST) and the zebrafish tail immobilization test (ZTI), also see Supplementary Tables S2-S5 and Table 2 in the main text for ANOVA data and post-hoc tests results. 5-HIAA - 5-hydroxyindoleacetic acid, DOPAC - 3,4-dihydroxyphenylacetic acid, HVA - homovanillic acid.

| Predictor | <i>b</i> | 95% CI | <i>t</i> (170) | <i>p</i> |
|--|----------|--------------------|----------------|----------|
| NTT distance traveled, cm Gauss distribution identity link | | | | |
| Intercept | 967.68 | [809.91, 1,125.45] | 12.02 | < .001 |
| Week2 | 187.50 | [-35.63, 410.62] | 1.65 | .101 |
| Week3 | 311.84 | [88.72, 534.96] | 2.74 | .007 |
| Week4 | 313.39 | [72.39, 554.39] | 2.55 | .012 |
| Week5 | 37.86 | [-203.14, 278.85] | 0.31 | .759 |
| GroupStress | 538.17 | [315.05, 761.29] | 4.73 | < .001 |
| Week2 × GroupStress | 30.89 | [-284.65, 346.43] | 0.19 | .848 |
| Week3 × GroupStress | -352.43 | [-667.97, -36.89] | -2.19 | .030 |
| Week4 × GroupStress | -339.79 | [-680.61, 1.03] | -1.95 | .052 |
| Week5 × GroupStress | -137.98 | [-478.80, 202.84] | -0.79 | .429 |
| NTT time spent not moving, s inverted Gauss distribution log link | | | | |
| Intercept | 3.75 | [3.22, 4.98] | 10.43 | < .001 |
| Week2 | -0.53 | [-1.81, 0.40] | -1.18 | .241 |
| Week3 | -0.77 | [-2.04, 0.07] | -1.77 | .079 |
| Week4 | -0.99 | [-2.26, -0.13] | -2.26 | .025 |
| Week5 | -0.07 | [-1.40, 1.54] | -0.13 | .896 |
| GroupStress | -0.84 | [-2.10, -0.02] | -1.95 | .053 |
| Week2 × GroupStress | -0.38 | [-1.46, 0.96] | -0.71 | .480 |
| Week3 × GroupStress | 1.17 | [0.07, 2.56] | 2.03 | .043 |
| Week4 × GroupStress | 0.73 | [-0.35, 2.10] | 1.32 | .190 |
| Week5 × GroupStress | 0.19 | [-1.50, 1.65] | 0.28 | .777 |
| NTT time spent in top, s Gauss distribution identity link | | | | |
| Intercept | 265.35 | [239.39, 291.32] | 20.03 | < .001 |
| Week2 | -129.30 | [-166.03, -92.58] | -6.90 | < .001 |
| Week3 | -69.49 | [-106.22, -32.77] | -3.71 | < .001 |
| Week4 | -108.22 | [-147.89, -68.55] | -5.35 | < .001 |
| Week5 | -100.75 | [-140.41, -61.08] | -4.98 | < .001 |
| GroupStress | -69.14 | [-105.87, -32.42] | -3.69 | < .001 |
| Week2 × GroupStress | -23.19 | [-75.12, 28.75] | -0.87 | .383 |
| Week3 × GroupStress | -78.34 | [-130.28, -26.40] | -2.96 | .004 |
| Week4 × GroupStress | -28.01 | [-84.11, 28.09] | -0.98 | .329 |
| Week5 × GroupStress | -69.98 | [-126.08, -13.88] | -2.45 | .016 |
| NTT top entries Gauss distribution identity link | | | | |
| Intercept | 4.35 | [0.63, 8.07] | 2.29 | .023 |
| Week2 | 9.70 | [4.44, 14.96] | 3.61 | < .001 |
| Week3 | 9.70 | [4.44, 14.96] | 3.61 | < .001 |
| Week4 | 11.05 | [5.37, 16.73] | 3.81 | < .001 |
| Week5 | 3.92 | [-1.77, 9.60] | 1.35 | .179 |
| GroupStress | 9.45 | [4.19, 14.71] | 3.52 | .001 |
| Week2 × GroupStress | -13.50 | [-20.94, -6.06] | -3.55 | < .001 |
| Week3 × GroupStress | -12.15 | [-19.59, -4.71] | -3.20 | .002 |
| Week4 × GroupStress | -13.72 | [-21.76, -5.68] | -3.34 | .001 |
| Week5 × GroupStress | -12.58 | [-20.62, -4.54] | -3.07 | .003 |
| NTT latency to top, s Gauss distribution identity link | | | | |
| Intercept | 28.97 | [-6.82, 64.76] | 1.59 | .114 |
| Week2 | 26.05 | [-24.56, 76.67] | 1.01 | .315 |
| Week3 | 26.15 | [-24.46, 76.77] | 1.01 | .313 |
| Week4 | 25.64 | [-29.03, 80.31] | 0.92 | .359 |
| Week5 | 17.29 | [-37.38, 71.96] | 0.62 | .536 |
| GroupStress | 19.34 | [-31.28, 69.95] | 0.75 | .455 |
| Week2 × GroupStress | 63.67 | [-7.91, 135.25] | 1.74 | .083 |
| Week3 × GroupStress | 46.57 | [-25.01, 118.14] | 1.28 | .204 |
| Week4 × GroupStress | 5.08 | [-72.23, 82.40] | 0.13 | .898 |
| Week5 × GroupStress | 111.87 | [34.55, 189.18] | 2.84 | .005 |
| LDT time spent in light, s Gauss distribution identity link | | | | |
| Intercept | 236.30 | [198.40, 274.20] | 12.22 | < .001 |

| | | | | |
|--|---------|-------------------|-------|--------|
| Week2 | -41.80 | [-95.40, 11.80] | -1.53 | .128 |
| Week3 | -53.75 | [-107.35, -0.15] | -1.97 | .051 |
| Week4 | -77.50 | [-135.40, -19.60] | -2.62 | .009 |
| Week5 | -82.23 | [-140.13, -24.34] | -2.78 | .006 |
| GroupStress | -141.20 | [-194.80, -87.60] | -5.16 | < .001 |
| Week2 × GroupStress | 29.10 | [-46.70, 104.90] | 0.75 | .453 |
| Week3 × GroupStress | 81.05 | [5.25, 156.85] | 2.10 | .038 |
| Week4 × GroupStress | 143.40 | [61.52, 225.28] | 3.43 | .001 |
| Week5 × GroupStress | 122.53 | [40.66, 204.41] | 2.93 | .004 |
| LDT number of light entries Gauss distribution identity link | | | | |
| Intercept | 6.50 | [3.82, 9.18] | 4.75 | < .001 |
| Week2 | 0.20 | [-3.59, 3.99] | 0.10 | .918 |
| Week3 | 4.35 | [0.56, 8.14] | 2.25 | .026 |
| Week4 | 3.63 | [-0.46, 7.73] | 1.74 | .084 |
| Week5 | 1.83 | [-2.26, 5.93] | 0.88 | .382 |
| GroupStress | -0.70 | [-4.49, 3.09] | -0.36 | .718 |
| Week2 × GroupStress | 0.85 | [-4.51, 6.21] | 0.31 | .756 |
| Week3 × GroupStress | -2.85 | [-8.21, 2.51] | -1.04 | .299 |
| Week4 × GroupStress | -2.17 | [-7.96, 3.63] | -0.73 | .464 |
| Week5 × GroupStress | 0.43 | [-5.36, 6.23] | 0.15 | .884 |
| ST average inter-fish distance, cm Gauss distribution identity link | | | | |
| Intercept | 1.40 | [1.26, 1.56] | 17.90 | < .001 |
| Week2 | 0.05 | [-0.17, 0.27] | 0.42 | .672 |
| Week3 | 0.18 | [-0.04, 0.42] | 1.59 | .113 |
| Week4 | 0.18 | [-0.06, 0.44] | 1.46 | .146 |
| Week5 | 0.35 | [0.10, 0.63] | 2.66 | .008 |
| GroupStress | 0.00 | [-0.22, 0.22] | 0.00 | .998 |
| Week2 × GroupStress | -0.18 | [-0.48, 0.13] | -1.15 | .250 |
| Week3 × GroupStress | -0.21 | [-0.52, 0.11] | -1.30 | .194 |
| Week4 × GroupStress | -0.28 | [-0.62, 0.06] | -1.61 | .109 |
| Week5 × GroupStress | -0.39 | [-0.75, -0.04] | -2.19 | .030 |
| ST distance to the surface, cm Gauss distribution identity link | | | | |
| Intercept | 11.34 | [9.41, 13.27] | 11.51 | < .001 |
| Week2 | -4.92 | [-7.65, -2.19] | -3.53 | .001 |
| Week3 | -3.06 | [-5.79, -0.33] | -2.20 | .029 |
| Week4 | 0.75 | [-2.19, 3.70] | 0.50 | .617 |
| Week5 | -3.73 | [-6.68, -0.78] | -2.48 | .014 |
| GroupStress | -5.40 | [-8.13, -2.67] | -3.87 | < .001 |
| Week2 × GroupStress | 11.15 | [7.29, 15.01] | 5.66 | < .001 |
| Week3 × GroupStress | 6.34 | [2.48, 10.20] | 3.22 | .001 |
| Week4 × GroupStress | 5.12 | [0.95, 9.29] | 2.41 | .017 |
| Week5 × GroupStress | 8.44 | [4.27, 12.61] | 3.97 | < .001 |
| ZTI time spent active, s Gauss distribution identity link | | | | |
| Intercept | 49.92 | [26.42, 73.41] | 4.16 | < .001 |
| Week2 | 18.06 | [-15.16, 51.28] | 1.07 | .288 |
| Week3 | -18.90 | [-52.12, 14.33] | -1.11 | .267 |
| Week4 | 5.23 | [-30.66, 41.11] | 0.29 | .776 |
| Week5 | -6.18 | [-42.07, 29.70] | -0.34 | .736 |
| GroupStress | -34.98 | [-68.20, -1.76] | -2.06 | .041 |
| Week2 × GroupStress | 32.74 | [-14.24, 79.72] | 1.37 | .174 |
| Week3 × GroupStress | 101.50 | [54.51, 148.48] | 4.23 | < .001 |
| Week4 × GroupStress | 22.28 | [-28.46, 73.03] | 0.86 | .391 |
| Week5 × GroupStress | 45.77 | [-4.97, 96.52] | 1.77 | .079 |
| Dopamine, pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 5.55 | [5.33, 5.83] | 44.47 | < .001 |
| Week2 | -0.12 | [-0.47, 0.22] | -0.71 | .479 |
| Week3 | 0.02 | [-0.33, 0.38] | 0.12 | .901 |
| Week4 | -0.20 | [-0.54, 0.13] | -1.17 | .244 |
| Week5 | -0.02 | [-0.38, 0.33] | -0.14 | .887 |
| GroupStress | -0.04 | [-0.39, 0.31] | -0.23 | .816 |
| Week2 × GroupStress | 0.22 | [-0.27, 0.71] | 0.89 | .375 |
| Week3 × GroupStress | 0.22 | [-0.29, 0.73] | 0.85 | .400 |
| Week4 × GroupStress | -0.05 | [-0.52, 0.41] | -0.22 | .828 |
| Week5 × GroupStress | 0.25 | [-0.25, 0.76] | 0.99 | .323 |
| DOPAC/dopamine ratio inverted Gauss distribution inverse link | | | | |
| Intercept | 9.00 | [5.47, 12.52] | 5.00 | < .001 |
| Week2 | -2.57 | [-7.19, 2.05] | -1.09 | .279 |
| Week3 | 0.49 | [-4.57, 5.54] | 0.19 | .851 |
| Week4 | -1.40 | [-6.19, 3.39] | -0.57 | .569 |
| Week5 | 0.29 | [-4.74, 5.32] | 0.11 | .909 |
| GroupStress | 0.85 | [-4.26, 5.95] | 0.33 | .745 |
| Week2 × GroupStress | -1.46 | [-8.02, 5.09] | -0.44 | .663 |
| Week3 × GroupStress | 4.68 | [-3.06, 12.43] | 1.19 | .239 |

| | | | | |
|--|---------|--------------------|-------|--------|
| Week4 × GroupStress | 0.17 | [-6.80, 7.13] | 0.05 | .962 |
| Week5 × GroupStress | -2.29 | [-9.35, 4.76] | -0.64 | .525 |
| DOPAC pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 3.37 | [3.02, 3.93] | 15.43 | < .001 |
| Week2 | 0.10 | [-0.57, 0.79] | 0.32 | .752 |
| Week3 | -0.06 | [-0.71, 0.59] | -0.18 | .856 |
| Week4 | -0.06 | [-0.71, 0.58] | -0.19 | .849 |
| Week5 | -0.14 | [-0.79, 0.48] | -0.47 | .639 |
| GroupStress | -0.26 | [-0.90, 0.33] | -0.91 | .368 |
| Week2 × GroupStress | 0.36 | [-0.53, 1.29] | 0.82 | .415 |
| Week3 × GroupStress | -0.02 | [-0.84, 0.81] | -0.04 | .967 |
| Week4 × GroupStress | 0.05 | [-0.78, 0.88] | 0.12 | .904 |
| 5-HIAA pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 5.24 | [4.97, 5.63] | 32.47 | < .001 |
| Week2 | -0.28 | [-0.73, 0.14] | -1.31 | .193 |
| Week3 | 0.02 | [-0.45, 0.49] | 0.07 | .941 |
| Week4 | -0.05 | [-0.51, 0.41] | -0.20 | .842 |
| Week5 | -0.15 | [-0.61, 0.29] | -0.69 | .489 |
| GroupStress | -0.15 | [-0.61, 0.29] | -0.69 | .495 |
| Week2 × GroupStress | 0.62 | [0.00, 1.27] | 1.96 | .053 |
| Week3 × GroupStress | -0.22 | [-0.84, 0.38] | -0.73 | .469 |
| Week4 × GroupStress | -0.45 | [-1.05, 0.14] | -1.52 | .132 |
| Week5 × GroupStress | 0.20 | [-0.40, 0.82] | 0.67 | .507 |
| 5-HIAA/serotonin ratio inverted Gauss distribution inverse link | | | | |
| Intercept | 1.58 | [1.03, 2.14] | 5.58 | < .001 |
| Week2 | 0.28 | [-0.54, 1.10] | 0.68 | .501 |
| Week3 | -0.11 | [-0.89, 0.66] | -0.28 | .777 |
| Week4 | -0.30 | [-1.05, 0.45] | -0.78 | .436 |
| Week5 | -0.07 | [-0.85, 0.71] | -0.17 | .868 |
| GroupStress | -0.03 | [-0.82, 0.75] | -0.09 | .932 |
| Week2 × GroupStress | -0.80 | [-1.89, 0.28] | -1.45 | .151 |
| Week3 × GroupStress | 1.46 | [0.25, 2.67] | 2.36 | .020 |
| Week4 × GroupStress | 1.06 | [-0.09, 2.21] | 1.81 | .073 |
| Week5 × GroupStress | 0.51 | [-0.63, 1.65] | 0.88 | .384 |
| Serotonin, pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 5.73 | [5.50, 6.04] | 42.77 | < .001 |
| Week2 | -0.09 | [-0.47, 0.28] | -0.48 | .635 |
| Week3 | -0.03 | [-0.41, 0.35] | -0.18 | .861 |
| Week4 | -0.10 | [-0.48, 0.27] | -0.53 | .596 |
| Week5 | -0.14 | [-0.51, 0.23] | -0.76 | .449 |
| GroupStress | -0.11 | [-0.49, 0.26] | -0.61 | .544 |
| Week2 × GroupStress | 0.10 | [-0.41, 0.62] | 0.40 | .688 |
| Week3 × GroupStress | 0.37 | [-0.16, 0.92] | 1.36 | .178 |
| Week4 × GroupStress | -0.01 | [-0.51, 0.50] | -0.03 | .976 |
| Week5 × GroupStress | 0.49 | [-0.04, 1.04] | 1.82 | .072 |
| HVA to dopamine ratio inverted Gauss distribution inverse link | | | | |
| Intercept | 37.70 | [20.26, 55.14] | 4.24 | < .001 |
| Week2 | 6.21 | [-19.45, 31.86] | 0.47 | .637 |
| Week3 | 19.85 | [-7.87, 47.57] | 1.40 | .164 |
| Week4 | -2.00 | [-26.33, 22.33] | -0.16 | .872 |
| Week5 | 1.31 | [-23.57, 26.19] | 0.10 | .918 |
| GroupStress | 13.78 | [-13.04, 40.61] | 1.01 | .317 |
| Week2 × GroupStress | -26.30 | [-62.72, 10.13] | -1.42 | .160 |
| Week3 × GroupStress | -5.22 | [-46.65, 36.22] | -0.25 | .806 |
| Week4 × GroupStress | 6.35 | [-31.83, 44.54] | 0.33 | .745 |
| Week5 × GroupStress | 13.55 | [-26.06, 53.16] | 0.67 | .504 |
| HVA, pg/mg inverted Gauss distribution inverse link | | | | |
| Intercept | 0.15 | [0.07, 0.22] | 3.99 | < .001 |
| Week2 | 0.05 | [-0.06, 0.15] | 0.81 | .418 |
| Week3 | 0.08 | [-0.03, 0.20] | 1.41 | .163 |
| Week4 | 0.03 | [-0.08, 0.13] | 0.47 | .638 |
| Week5 | 0.03 | [-0.08, 0.14] | 0.56 | .579 |
| GroupStress | 0.08 | [-0.03, 0.20] | 1.42 | .159 |
| Week2 × GroupStress | -0.13 | [-0.29, 0.03] | -1.62 | .109 |
| Week3 × GroupStress | -0.10 | [-0.27, 0.07] | -1.12 | .267 |
| Week4 × GroupStress | 0.04 | [-0.13, 0.22] | 0.50 | .620 |
| Week5 × GroupStress | 0.00 | [-0.17, 0.17] | 0.01 | .990 |
| Norepinephrine, pg/mg Gauss distribution identity link | | | | |
| Intercept | 913.44 | [678.49, 1,148.38] | 7.62 | < .001 |
| Week2 | -163.89 | [-496.16, 168.37] | -0.97 | .336 |
| Week3 | -106.53 | [-438.79, 225.73] | -0.63 | .531 |
| Week4 | -197.99 | [-530.25, 134.27] | -1.17 | .246 |
| Week5 | 105.58 | [-226.69, 437.84] | 0.62 | .535 |

| | | | | |
|---------------------|--------|-------------------|-------|------|
| GroupStress | -78.08 | [-410.34, 254.18] | -0.46 | .646 |
| Week2 × GroupStress | 254.60 | [-215.29, 724.49] | 1.06 | .291 |
| Week3 × GroupStress | 463.23 | [-6.67, 933.12] | 1.93 | .056 |
| Week4 × GroupStress | 100.21 | [-369.68, 570.11] | 0.42 | .677 |
| Week5 × GroupStress | 310.81 | [-159.08, 780.71] | 1.30 | .198 |

Supplementary Table S3. Post-hoc Tukey’s test results for significant group predictor ANOVA data pair-wise comparison using the Generalized Linear Model (GZLM) with week, group and their interaction effects as predictors comparing stress and control group at 1-5 weeks of the chronic unpredictable stress (CUS) for the novel tank test (NTT), light-dark test (LDT), shoaling test (ST) and zebrafish tail immobilization (ZTI) test, also see Supplementary Tables S1, S3-S5 and Tables 2-3 in the main text for GZLM, ANOVA and other post-hoc test results. 5-HIAA - 5-hydroxyindoleacetic acid.

| Endpoints | ΔM | 95% CI | <i>z</i>.ratio | <i>p</i> |
|---------------------------------|------------------------------|--------------------|-----------------------|-----------------|
| NTT Distance traveled, cm | -378.31 | [-484.54, -272.08] | -6.98 | < .001 |
| NTT Time spent not moving, s | 0.50 | [0.15, 0.85] | 2.80 | .005 |
| NTT Time spent in top, s | 109.05 | [91.56, 126.53] | 12.22 | < .001 |
| NTT Latency to enter the top, s | -64.77 | [-88.87, -40.68] | -5.27 | < .001 |
| LDB Time spent in light, s | 65.98 | [40.46, 91.50] | 5.07 | < .001 |
| ST inter-fish distance, cm | 0.21 | [0.10, 0.32] | 3.87 | < .001 |
| 5-HIAA/serotonin ratio | -0.41 | [-0.78, -0.04] | -2.18 | .029 |

Supplementary Table S4. Results of post-hoc Tukey's test for significant week predictor ANOVA data pair-wise comparison using Generalized Linear Model (GZLM) with week, group and their interaction effects as 'predictors', comparing stress and control group at 1-5 weeks of the chronic unpredictable stress (CUS) for the novel tank test (NTT), the light-dark test (LDT), shoaling test (ST) and the zebrafish tail immobilization test (ZTI), also see Supplementary Tables S1-S2, S4-S5 and Table 2 in the main text for GZLM, ANOVA and other post-hoc test results. DOPAC - 3,4-dihydroxyphenylacetic acid.

| Comparisons (week vs week) | ΔM | 95% CI | <i>z</i> .ratio | <i>p</i> |
|-------------------------------------|------------|-------------------|-----------------|----------|
| NTT Distance traveled, cm | | | | |
| 1 - 2 | -202.94 | [-360.71, -45.17] | -2.52 | .012 |
| 1 - 3 | -135.63 | [-293.40, 22.14] | -1.68 | .092 |
| 1 - 4 | -143.49 | [-313.90, 26.92] | -1.65 | .099 |
| 1 - 5 | 31.14 | [-139.28, 201.55] | 0.36 | .720 |
| 2 - 3 | 67.31 | [-90.46, 225.08] | 0.84 | .403 |
| 2 - 4 | 59.44 | [-110.97, 229.86] | 0.68 | .494 |
| 2 - 5 | 234.07 | [63.66, 404.49] | 2.69 | .007 |
| 3 - 4 | -7.87 | [-178.28, 162.55] | -0.09 | .928 |
| 3 - 5 | 166.76 | [-3.65, 337.17] | 1.92 | .055 |
| 4 - 5 | 174.63 | [-7.55, 356.81] | 1.88 | .060 |
| NTT Time spent not moving, s | | | | |
| 1 - 2 | 0.72 | [0.20, 1.24] | 2.71 | .007 |
| 1 - 3 | 0.19 | [-0.38, 0.75] | 0.65 | .517 |
| 1 - 4 | 0.63 | [0.09, 1.17] | 2.27 | .023 |
| 1 - 5 | -0.02 | [-0.67, 0.62] | -0.07 | .945 |
| 2 - 3 | -0.54 | [-1.02, -0.05] | -2.18 | .029 |
| 2 - 4 | -0.09 | [-0.55, 0.37] | -0.40 | .688 |
| 2 - 5 | -0.75 | [-1.32, -0.17] | -2.54 | .011 |
| 3 - 4 | 0.44 | [-0.06, 0.95] | 1.72 | .085 |
| 3 - 5 | -0.21 | [-0.82, 0.40] | -0.67 | .503 |
| 4 - 5 | -0.65 | [-1.24, -0.06] | -2.15 | .031 |
| NTT Time spent in top, s | | | | |
| 1 - 2 | 140.90 | [114.93, 166.87] | 10.63 | < .001 |
| 1 - 3 | 108.66 | [82.69, 134.63] | 8.20 | < .001 |
| 1 - 4 | 122.22 | [94.17, 150.27] | 8.54 | < .001 |
| 1 - 5 | 135.74 | [107.69, 163.79] | 9.48 | < .001 |
| 2 - 3 | -32.23 | [-58.20, -6.27] | -2.43 | .015 |
| 2 - 4 | -18.67 | [-46.72, 9.38] | -1.30 | .192 |
| 2 - 5 | -5.16 | [-33.21, 22.89] | -0.36 | .718 |
| 3 - 4 | 13.56 | [-14.49, 41.61] | 0.95 | .343 |
| 3 - 5 | 27.08 | [-0.97, 55.12] | 1.89 | .059 |
| 4 - 5 | 13.51 | [-16.47, 43.50] | 0.88 | .377 |
| NTT Number of top entries | | | | |
| 1 - 2 | -2.95 | [-6.67, 0.77] | -1.55 | .120 |
| 1 - 3 | -3.63 | [-7.35, 0.10] | -1.91 | .056 |
| 1 - 4 | -4.19 | [-8.21, -0.17] | -2.04 | .041 |
| 1 - 5 | 2.37 | [-1.64, 6.39] | 1.16 | .247 |
| 2 - 3 | -0.68 | [-4.40, 3.05] | -0.36 | .722 |
| 2 - 4 | -1.24 | [-5.26, 2.78] | -0.61 | .545 |
| 2 - 5 | 5.32 | [1.31, 9.34] | 2.60 | .009 |
| 3 - 4 | -0.57 | [-4.59, 3.45] | -0.28 | .782 |
| 3 - 5 | 6.00 | [1.98, 10.02] | 2.93 | .003 |
| 4 - 5 | 6.57 | [2.27, 10.86] | 3.00 | .003 |
| NTT Latency to enter top, s | | | | |
| 1 - 2 | -57.89 | [-93.68, -22.10] | -3.17 | .002 |
| 1 - 3 | -49.43 | [-85.22, -13.65] | -2.71 | .007 |
| 1 - 4 | -28.18 | [-66.84, 10.48] | -1.43 | .153 |
| 1 - 5 | -73.22 | [-111.88, -34.56] | -3.71 | < .001 |
| 2 - 3 | 8.45 | [-27.34, 44.24] | 0.46 | .644 |
| 2 - 4 | 29.71 | [-8.95, 68.37] | 1.51 | .132 |
| 2 - 5 | -15.33 | [-53.99, 23.32] | -0.78 | .437 |
| 3 - 4 | 21.26 | [-17.40, 59.91] | 1.08 | .281 |
| 3 - 5 | -23.79 | [-62.44, 14.87] | -1.21 | .228 |
| 4 - 5 | -45.04 | [-86.37, -3.72] | -2.14 | .033 |
| ST Distance to surface, cm | | | | |
| 1 - 2 | -0.66 | [-2.59, 1.27] | -0.67 | .504 |
| 1 - 3 | -0.11 | [-2.04, 1.82] | -0.11 | .909 |
| 1 - 4 | -3.31 | [-5.40, -1.23] | -3.11 | .002 |

| | | | | |
|---------------------------------|---------|--------------------|-------|------|
| 1 - 5 | -0.49 | [-2.58, 1.59] | -0.46 | .645 |
| 2 - 3 | 0.55 | [-1.38, 2.48] | 0.56 | .579 |
| 2 - 4 | -2.65 | [-4.74, -0.57] | -2.50 | .013 |
| 2 - 5 | 0.17 | [-1.92, 2.25] | 0.16 | .874 |
| 3 - 4 | -3.20 | [-5.29, -1.12] | -3.01 | .003 |
| 3 - 5 | -0.38 | [-2.46, 1.71] | -0.36 | .722 |
| 4 - 5 | 2.82 | [0.59, 5.05] | 2.48 | .013 |
| ZTI Time spent active, s | | | | |
| 1 - 2 | -34.43 | [-57.92, -10.94] | -2.87 | .004 |
| 1 - 3 | -31.85 | [-55.34, -8.36] | -2.66 | .008 |
| 1 - 4 | -16.37 | [-41.74, 9.00] | -1.26 | .206 |
| 1 - 5 | -16.70 | [-42.08, 8.67] | -1.29 | .197 |
| 2 - 3 | 2.58 | [-20.92, 26.07] | 0.21 | .830 |
| 2 - 4 | 18.06 | [-7.31, 43.43] | 1.39 | .163 |
| 2 - 5 | 17.72 | [-7.65, 43.10] | 1.37 | .171 |
| 3 - 4 | 15.48 | [-9.89, 40.86] | 1.20 | .232 |
| 3 - 5 | 15.15 | [-10.22, 40.52] | 1.17 | .242 |
| 4 - 5 | -0.33 | [-27.46, 26.79] | -0.02 | .981 |
| Dopamine, pg/mg | | | | |
| 1 - 2 | 0.01 | [-0.23, 0.25] | 0.10 | .923 |
| 1 - 3 | -0.13 | [-0.38, 0.12] | -1.02 | .309 |
| 1 - 4 | 0.22 | [-0.01, 0.45] | 1.90 | .057 |
| 1 - 5 | -0.10 | [-0.35, 0.15] | -0.80 | .426 |
| 2 - 3 | -0.14 | [-0.39, 0.11] | -1.11 | .266 |
| 2 - 4 | 0.21 | [-0.02, 0.44] | 1.80 | .071 |
| 2 - 5 | -0.11 | [-0.36, 0.14] | -0.89 | .372 |
| 3 - 4 | 0.35 | [0.11, 0.59] | 2.90 | .004 |
| 3 - 5 | 0.03 | [-0.23, 0.29] | 0.22 | .825 |
| 4 - 5 | -0.32 | [-0.56, -0.09] | -2.68 | .007 |
| DOPAC/dopamine ratio | | | | |
| 1 - 2 | 3.30 | [0.02, 6.58] | 1.97 | .049 |
| 1 - 3 | -2.83 | [-6.70, 1.04] | -1.43 | .152 |
| 1 - 4 | 1.31 | [-2.17, 4.79] | 0.74 | .460 |
| 1 - 5 | 0.85 | [-2.67, 4.38] | 0.47 | .635 |
| 2 - 3 | -6.13 | [-9.69, -2.56] | -3.37 | .001 |
| 2 - 4 | -1.99 | [-5.12, 1.15] | -1.24 | .214 |
| 2 - 5 | -2.45 | [-5.63, 0.74] | -1.50 | .133 |
| 3 - 4 | 4.14 | [0.39, 7.89] | 2.16 | .031 |
| 3 - 5 | 3.68 | [-0.11, 7.48] | 1.90 | .057 |
| 4 - 5 | -0.46 | [-3.85, 2.94] | -0.26 | .792 |
| Norepinephrine, pg/mg | | | | |
| 1 - 2 | 36.59 | [-198.35, 271.54] | 0.31 | .760 |
| 1 - 3 | -125.08 | [-360.03, 109.86] | -1.04 | .297 |
| 1 - 4 | 147.88 | [-87.06, 382.83] | 1.23 | .217 |
| 1 - 5 | -260.98 | [-495.93, -26.04] | -2.18 | .029 |
| 2 - 3 | -161.68 | [-396.62, 73.27] | -1.35 | .177 |
| 2 - 4 | 111.29 | [-123.65, 346.24] | 0.93 | .353 |
| 2 - 5 | -297.58 | [-532.52, -62.63] | -2.48 | .013 |
| 3 - 4 | 272.97 | [38.02, 507.91] | 2.28 | .023 |
| 3 - 5 | -135.90 | [-370.85, 99.04] | -1.13 | .257 |
| 4 - 5 | -408.87 | [-643.81, -173.92] | -3.41 | .001 |

Supplementary Table S5. Results of post-hoc Tukey's test for significant group x week interaction predictor ANOVA data pair-wise comparison of group differences within the same week, using Generalized Linear Model (GZLM) with week, group and their interaction effects as predictors to compare stress and control group at weeks 1-5 for the novel tank test (NTT), the light-dark test (LDT), shoaling test (ST) and the zebrafish tail immobilization test (ZTI). 5-HIAA - 5-hydroxyindoleacetic acid.

| Comparisons (group vs. group within the same week) | ΔM | 95% CI | <i>z</i> ratio | <i>p</i> |
|--|------------|-------------------|----------------|----------|
| NTT Time spent not moving, s | | | | |
| 1,Control - 1,Stress | 0.84 | [0.00, 1.68] | 1.95 | .051 |
| 2,Control - 2,Stress | 1.22 | [0.60, 1.83] | 3.88 | < .001 |
| 3,Control - 3,Stress | -0.33 | [-1.07, 0.42] | -0.86 | .388 |
| 4,Control - 4,Stress | 0.11 | [-0.57, 0.79] | 0.32 | .751 |
| 5,Control - 5,Stress | 0.65 | [-0.32, 1.62] | 1.32 | .186 |
| NTT Time spent in top, s | | | | |
| 1,Control - 1,Stress | 69.14 | [32.42, 105.87] | 3.69 | < .001 |
| 2,Control - 2,Stress | 92.33 | [55.60, 129.05] | 4.93 | < .001 |
| 3,Control - 3,Stress | 147.48 | [110.75, 184.21] | 7.87 | < .001 |
| 4,Control - 4,Stress | 97.15 | [54.74, 139.56] | 4.49 | < .001 |
| 5,Control - 5,Stress | 139.13 | [96.72, 181.53] | 6.43 | < .001 |
| NTT Number of top entries | | | | |
| 1,Control - 1,Stress | -9.45 | [-14.71, -4.19] | -3.52 | < .001 |
| 2,Control - 2,Stress | 4.05 | [-1.21, 9.31] | 1.51 | .131 |
| 3,Control - 3,Stress | 2.70 | [-2.56, 7.96] | 1.01 | .315 |
| 4,Control - 4,Stress | 4.27 | [-1.81, 10.34] | 1.38 | .169 |
| 5,Control - 5,Stress | 3.13 | [-2.94, 9.21] | 1.01 | .312 |
| NTT Latency to enter the top, s | | | | |
| 1,Control - 1,Stress | -19.34 | [-69.95, 31.28] | -0.75 | .454 |
| 2,Control - 2,Stress | -83.01 | [-133.62, -32.39] | -3.21 | .001 |
| 3,Control - 3,Stress | -65.90 | [-116.52, -15.29] | -2.55 | .011 |
| 4,Control - 4,Stress | -24.42 | [-82.86, 34.03] | -0.82 | .413 |
| 5,Control - 5,Stress | -131.20 | [-189.65, -72.76] | -4.40 | < .001 |
| LDT Time spent in light, s | | | | |
| 1,Control - 1,Stress | 141.20 | [87.60, 194.80] | 5.16 | < .001 |
| 2,Control - 2,Stress | 112.10 | [58.50, 165.70] | 4.10 | < .001 |
| 3,Control - 3,Stress | 60.15 | [6.55, 113.75] | 2.20 | .028 |
| 4,Control - 4,Stress | -2.20 | [-64.09, 59.69] | -0.07 | .944 |
| 5,Control - 5,Stress | 18.67 | [-43.23, 80.56] | 0.59 | .554 |
| ST Distance to surface, cm | | | | |
| 1,Control - 1,Stress | 5.40 | [2.67, 8.13] | 3.87 | < .001 |
| 2,Control - 2,Stress | -5.76 | [-8.49, -3.03] | -4.13 | < .001 |
| 3,Control - 3,Stress | -0.95 | [-3.68, 1.78] | -0.68 | .497 |
| 4,Control - 4,Stress | 0.28 | [-2.87, 3.43] | 0.17 | .863 |
| 5,Control - 5,Stress | -3.04 | [-6.19, 0.11] | -1.89 | .059 |
| ZTI Time spent active, s | | | | |
| 1,Control - 1,Stress | 34.98 | [1.76, 68.20] | 2.06 | .039 |
| 2,Control - 2,Stress | 2.24 | [-30.98, 35.46] | 0.13 | .895 |
| 3,Control - 3,Stress | -66.52 | [-99.74, -33.30] | -3.92 | < .001 |
| 4,Control - 4,Stress | 12.69 | [-25.67, 51.05] | 0.65 | .517 |
| 5,Control - 5,Stress | -10.80 | [-49.16, 27.56] | -0.55 | .581 |
| 5-HIAA, pg/mg | | | | |
| 1,Control - 1,Stress | 0.15 | [-0.28, 0.58] | 0.69 | .493 |
| 2,Control - 2,Stress | -0.47 | [-0.91, -0.02] | -2.07 | .038 |
| 3,Control - 3,Stress | 0.37 | [-0.04, 0.79] | 1.76 | .078 |
| 4,Control - 4,Stress | 0.60 | [0.22, 0.99] | 3.05 | .002 |
| 5,Control - 5,Stress | -0.05 | [-0.47, 0.37] | -0.25 | .803 |
| 5-HIAA/serotonin ratio | | | | |
| 1,Control - 1,Stress | 0.03 | [-0.75, 0.82] | 0.09 | .932 |
| 2,Control - 2,Stress | 0.84 | [0.08, 1.59] | 2.18 | .029 |
| 3,Control - 3,Stress | -1.43 | [-2.35, -0.50] | -3.03 | .002 |
| 4,Control - 4,Stress | -1.03 | [-1.87, -0.19] | -2.40 | .016 |
| 5,Control - 5,Stress | -0.47 | [-1.30, 0.35] | -1.12 | .261 |

Supplementary Table S6. Results of generalized Linear Model (GZLM) fits using group as ‘predictor’ to compare control, stress and fluoxetine groups at 5th week of chronic unpredictable stress (CUS). The corrected Akaike information criterion (AIC) was used to choose the ‘best fit’ model among Gaussian distribution (identity link), Poisson distribution (with log link), Gamma distribution (inverse and log links) and Inverse Gaussian distribution (with inverse and log links) for the novel tank test (NTT), the light-dark test (LDT), shoaling test (ST) and the zebrafish tail immobilization test (ZTI), also see Table 3 in the main text for ANOVA and post-hoc tests results. 5-HIAA - 5-hydroxyindoleacetic acid, DOPAC - 3,4-dihydroxyphenylacetic acid, HVA - homovanillic acid.

| Predictor | <i>b</i> | 95% CI | <i>t</i> (42) | <i>p</i> |
|--|----------|--------------------|---------------|----------|
| ZTI Time spent active, s Gauss distribution identity link | | | | |
| Intercept | 43.73 | [18.90, 68.56] | 3.45 | .001 |
| GroupFluoxetine | 2.24 | [-32.88, 37.36] | 0.13 | .901 |
| GroupStress | 10.80 | [-24.32, 45.92] | 0.60 | .550 |
| NTT Distance traveled, cm Gauss distribution identity link | | | | |
| Intercept | 1,005.54 | [835.31, 1,175.77] | 11.58 | < .001 |
| GroupFluoxetine | 28.33 | [-212.41, 269.06] | 0.23 | .819 |
| GroupStress | 400.19 | [159.45, 640.93] | 3.26 | .002 |
| ST Inter-fish distance, cm Gamma distribution log link | | | | |
| Intercept | 1.75 | [1.58, 1.94] | 19.18 | < .001 |
| GroupFluoxetine | -0.09 | [-0.34, 0.17] | -0.67 | .508 |
| GroupStress | -0.39 | [-0.64, -0.14] | -3.01 | .004 |
| NTT Time spent not moving, s inverted Gauss distribution log link | | | | |
| Intercept | 3.68 | [3.20, 4.64] | 11.72 | < .001 |
| GroupFluoxetine | -0.53 | [-1.55, 0.27] | -1.33 | .192 |
| GroupStress | -0.65 | [-1.67, 0.10] | -1.69 | .099 |
| NTT Time spent in top, s Gauss distribution identity link | | | | |
| Intercept | 164.61 | [131.03, 198.19] | 9.61 | < .001 |
| GroupFluoxetine | -41.10 | [-88.59, 6.39] | -1.70 | .097 |
| GroupStress | -139.13 | [-186.61, -91.64] | -5.74 | < .001 |
| NTT Number of top entries Gauss distribution identity link | | | | |
| Intercept | 8.27 | [5.10, 11.43] | 5.12 | < .001 |
| GroupFluoxetine | 0.27 | [-4.21, 4.74] | 0.12 | .908 |
| GroupStress | -3.13 | [-7.61, 1.34] | -1.37 | .178 |
| NTT Latency to enter the top, s Gauss distribution identity link | | | | |
| Intercept | 46.26 | [1.49, 91.03] | 2.03 | .049 |
| GroupFluoxetine | 31.44 | [-31.88, 94.75] | 0.97 | .336 |
| GroupStress | 131.20 | [67.89, 194.52] | 4.06 | < .001 |
| LDT Time spent in light, s Gauss distribution identity link | | | | |
| Intercept | 154.07 | [113.70, 194.43] | 7.48 | < .001 |
| GroupFluoxetine | -8.07 | [-65.15, 49.02] | -0.28 | .783 |
| GroupStress | -18.67 | [-75.75, 38.42] | -0.64 | .525 |
| LDT Number of light entries Gauss distribution identity link | | | | |
| Intercept | 8.33 | [5.51, 11.16] | 5.78 | < .001 |
| GroupFluoxetine | -1.40 | [-5.40, 2.60] | -0.69 | .496 |
| GroupStress | -0.27 | [-4.27, 3.73] | -0.13 | .897 |
| ST Distance to surface, cm Gamma distribution inverse link | | | | |
| Intercept | 2.03 | [1.78, 2.30] | 15.23 | < .001 |
| GroupFluoxetine | 0.10 | [-0.27, 0.47] | 0.51 | .613 |
| GroupStress | 0.34 | [-0.03, 0.71] | 1.79 | .080 |
| Dopamine, pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 5.52 | [5.24, 5.91] | 33.49 | < .001 |
| GroupFluoxetine | 0.06 | [-0.42, 0.55] | 0.25 | .803 |
| GroupStress | 0.21 | [-0.28, 0.73] | 0.86 | .399 |
| DOPAC/dopamine ratio Gamma distribution inverted link | | | | |
| Intercept | 9.29 | [6.37, 12.99] | 5.52 | < .001 |
| GroupFluoxetine | -0.81 | [-5.39, 3.68] | -0.35 | .726 |
| GroupStress | -1.45 | [-5.92, 2.85] | -0.66 | .517 |
| DOPAC pg/mg Gamma distribution log link | | | | |
| Intercept | 3.23 | [2.87, 3.65] | 16.32 | < .001 |
| GroupFluoxetine | 0.20 | [-0.36, 0.75] | 0.70 | .489 |
| GroupStress | 0.37 | [-0.18, 0.92] | 1.32 | .198 |
| 5-HIAA, pg/mg Gamma distribution log link | | | | |
| Intercept | 5.09 | [4.78, 5.44] | 30.38 | < .001 |
| GroupFluoxetine | -0.84 | [-1.30, -0.37] | -3.52 | .002 |
| GroupStress | 0.05 | [-0.41, 0.52] | 0.23 | .823 |
| 5-HIAA/serotonin inverted Gauss distribution log link | | | | |
| Intercept | -0.42 | [-0.82, 0.26] | -1.66 | .108 |

| | | | | |
|--|-------|-----------------|-------|--------|
| GroupFluoxetine | -0.89 | [-1.62, -0.34] | -2.98 | .006 |
| GroupStress | -0.27 | [-1.03, 0.41] | -0.82 | .422 |
| Serotonin, pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 5.59 | [5.34, 5.93] | 37.89 | < .001 |
| GroupFluoxetine | 0.03 | [-0.40, 0.46] | 0.14 | .886 |
| GroupStress | 0.38 | [-0.08, 0.87] | 1.63 | .114 |
| HVA/dopamine inverted Gauss distribution inverse link | | | | |
| Intercept | 39.01 | [21.75, 56.27] | 4.43 | < .001 |
| GroupFluoxetine | 8.82 | [-16.94, 34.57] | 0.67 | .508 |
| GroupStress | 27.33 | [-1.03, 55.70] | 1.89 | .070 |
| HVA, pg/mg inverted Gauss distribution log link | | | | |
| Intercept | 1.73 | [1.43, 2.18] | 9.51 | < .001 |
| GroupFluoxetine | -0.09 | [-0.62, 0.43] | -0.36 | .724 |
| GroupStress | -0.39 | [-0.90, 0.07] | -1.66 | .109 |
| Norepinephrine, pg/mg inverted Gauss log link | | | | |
| Intercept | 6.93 | [6.66, 7.29] | 44.75 | < .001 |
| GroupFluoxetine | -0.01 | [-0.45, 0.44] | -0.03 | .980 |
| GroupStress | 0.21 | [-0.26, 0.69] | 0.89 | .381 |

Supplementary Table S7. Results of Generalized Linear Model (GZLM) fits using week, group, their interaction effects and the involvement in behavioral battery as ‘predictors’ to compare stress and control group at weeks 1-5 of chronic unpredictable stress (CUS). The corrected Akaike information criterion (AIC) was used to choose the ‘best fit’ model among Gaussian distribution (identity link), Poisson distribution (with log link), Gamma distribution (inverse and log links) and Inverse Gaussian distribution (with inverse and log links) for levels of serotonin, dopamine, norepinephrine and their metabolites in the whole brain tissue using HPLC. behaviors assessed in the present study. Because no significant effects were observed for behavioral predictor in any models, it was excluded from further analyses, also see Supplementary Table S1 for details of GZLMs utilized in this study. Monoamine metabolites assessed here included 5-HIAA - 5-hydroxyindoleacetic acid, DOPAC - 3,4-dihydroxyphenylacetic acid, and HVA - homovanillic acid.

| Predictor | <i>b</i> | 95% CI | <i>t</i> (170) | <i>p</i> |
|-------------------------------|----------|----------------|----------------|----------|
| Dopamine pg/mg | | | | |
| Intercept | 5.54 | [5.31, 5.83] | 42.22 | < .001 |
| Week2 | -0.12 | [-0.47, 0.22] | -0.71 | .480 |
| Week3 | 0.02 | [-0.34, 0.38] | 0.12 | .902 |
| Week4 | -0.20 | [-0.54, 0.14] | -1.17 | .246 |
| Week5 | -0.03 | [-0.38, 0.33] | -0.14 | .887 |
| GroupStress | -0.04 | [-0.40, 0.31] | -0.23 | .816 |
| BehaviorN | 0.00 | [-0.15, 0.16] | 0.06 | .956 |
| Week2 × GroupStress | 0.22 | [-0.27, 0.72] | 0.89 | .377 |
| Week3 × GroupStress | 0.22 | [-0.29, 0.73] | 0.84 | .402 |
| Week4 × GroupStress | -0.05 | [-0.52, 0.42] | -0.22 | .830 |
| Week5 × GroupStress | 0.25 | [-0.25, 0.76] | 0.99 | .325 |
| DOPAC/dopamine ratio | | | | |
| Intercept | 8.86 | [5.21, 12.51] | 4.69 | < .001 |
| Week2 | -2.55 | [-7.19, 2.09] | -1.08 | .285 |
| Week3 | 0.44 | [-4.64, 5.52] | 0.17 | .866 |
| Week4 | -1.37 | [-6.18, 3.44] | -0.56 | .578 |
| Week5 | 0.24 | [-4.82, 5.30] | 0.09 | .927 |
| GroupStress | 0.79 | [-4.34, 5.93] | 0.30 | .762 |
| BehaviorN | 0.33 | [-1.89, 2.55] | 0.30 | .765 |
| Week2 × GroupStress | -1.52 | [-8.10, 5.07] | -0.45 | .652 |
| Week3 × GroupStress | 4.76 | [-3.03, 12.54] | 1.20 | .233 |
| Week4 × GroupStress | 0.20 | [-6.79, 7.19] | 0.06 | .955 |
| Week5 × GroupStress | -2.23 | [-9.32, 4.86] | -0.62 | .538 |
| DOPAC, pg/mg | | | | |
| Intercept | 3.41 | [3.04, 3.96] | 15.04 | < .001 |
| Week2 | 0.10 | [-0.56, 0.78] | 0.32 | .748 |
| Week3 | -0.02 | [-0.67, 0.63] | -0.07 | .944 |
| Week4 | -0.06 | [-0.71, 0.57] | -0.21 | .835 |
| Week5 | -0.10 | [-0.75, 0.53] | -0.33 | .746 |
| GroupStress | -0.22 | [-0.86, 0.38] | -0.77 | .443 |
| BehaviorN | -0.11 | [-0.39, 0.18] | -0.80 | .423 |
| Week2 × GroupStress | 0.37 | [-0.51, 1.30] | 0.85 | .400 |
| Week3 × GroupStress | -0.08 | [-0.91, 0.76] | -0.19 | .851 |
| Week4 × GroupStress | 0.01 | [-0.81, 0.84] | 0.03 | .973 |
| Week5 × GroupStress | 0.58 | [-0.28, 1.50] | 1.35 | .182 |
| 5-HIAA pg/mg | | | | |
| Intercept | 5.21 | [4.92, 5.54] | 32.49 | < .001 |
| Week2 | -0.29 | [-0.72, 0.13] | -1.35 | .180 |
| Week3 | 0.01 | [-0.42, 0.43] | 0.03 | .974 |
| Week4 | -0.05 | [-0.48, 0.37] | -0.25 | .801 |
| Week5 | -0.17 | [-0.59, 0.26] | -0.77 | .444 |
| GroupStress | -0.17 | [-0.60, 0.26] | -0.78 | .435 |
| BehaviorN | 0.08 | [-0.11, 0.27] | 0.82 | .417 |
| Week2 × GroupStress | 0.64 | [0.04, 1.25] | 2.10 | .038 |
| Week3 × GroupStress | -0.20 | [-0.80, 0.40] | -0.66 | .513 |
| Week4 × GroupStress | -0.42 | [-1.03, 0.18] | -1.38 | .172 |
| Week5 × GroupStress | 0.23 | [-0.38, 0.83] | 0.74 | .462 |
| 5-HIAA/serotonin ratio | | | | |
| Intercept | 1.64 | [1.05, 2.23] | 5.38 | < .001 |
| Week2 | 0.30 | [-0.55, 1.14] | 0.69 | .492 |
| Week3 | -0.09 | [-0.89, 0.70] | -0.23 | .816 |
| Week4 | -0.29 | [-1.06, 0.47] | -0.76 | .451 |

| | | | | |
|------------------------------|---------|--------------------|--------|--------|
| Week5 | -0.04 | [-0.84, 0.76] | -0.10 | .923 |
| GroupStress | -0.01 | [-0.81, 0.79] | -0.03 | .979 |
| BehaviorN | -0.13 | [-0.50, 0.24] | -0.70 | .484 |
| Week2 × GroupStress | -0.82 | [-1.93, 0.29] | -1.44 | .153 |
| Week3 × GroupStress | 1.44 | [0.19, 2.68] | 2.27 | .026 |
| Week4 × GroupStress | 1.02 | [-0.16, 2.20] | 1.71 | .091 |
| Week5 × GroupStress | 0.47 | [-0.70, 1.64] | 0.79 | .433 |
| Serotonin, pg/mg | | | | |
| Intercept | 5.75 | [5.50, 6.06] | 40.86 | < .001 |
| Week2 | -0.09 | [-0.47, 0.28] | -0.47 | .638 |
| Week3 | -0.03 | [-0.42, 0.34] | -0.18 | .857 |
| Week4 | -0.10 | [-0.47, 0.27] | -0.52 | .602 |
| Week5 | -0.14 | [-0.52, 0.22] | -0.78 | .440 |
| GroupStress | -0.11 | [-0.49, 0.26] | -0.59 | .557 |
| BehaviorN | -0.03 | [-0.20, 0.14] | -0.36 | .721 |
| Week2 × GroupStress | 0.09 | [-0.42, 0.61] | 0.36 | .722 |
| Week3 × GroupStress | 0.36 | [-0.17, 0.91] | 1.34 | .185 |
| Week4 × GroupStress | -0.01 | [-0.52, 0.50] | -0.04 | .970 |
| Week5 × GroupStress | 0.49 | [-0.04, 1.04] | 1.82 | .073 |
| HVA/dopamine ratio | | | | |
| Intercept | -3.64 | [-4.03, -3.01] | -14.77 | < .001 |
| Week2 | -0.17 | [-0.90, 0.52] | -0.53 | .599 |
| Week3 | -0.44 | [-1.14, 0.18] | -1.43 | .157 |
| Week4 | 0.07 | [-0.67, 0.83] | 0.19 | .848 |
| Week5 | -0.04 | [-0.76, 0.68] | -0.11 | .913 |
| GroupStress | -0.32 | [-1.03, 0.31] | -1.02 | .309 |
| BehaviorN | 0.04 | [-0.25, 0.32] | 0.27 | .791 |
| Week2 × GroupStress | 0.66 | [-0.26, 1.66] | 1.44 | .153 |
| Week3 × GroupStress | 0.19 | [-0.64, 1.04] | 0.46 | .649 |
| Week4 × GroupStress | -0.15 | [-1.08, 0.76] | -0.34 | .735 |
| Week5 × GroupStress | -0.21 | [-1.10, 0.66] | -0.50 | .619 |
| HVA, pg/mg | | | | |
| Intercept | 0.14 | [0.07, 0.22] | 3.65 | < .001 |
| Week2 | 0.04 | [-0.07, 0.15] | 0.77 | .446 |
| Week3 | 0.08 | [-0.04, 0.20] | 1.37 | .173 |
| Week4 | 0.03 | [-0.08, 0.13] | 0.49 | .627 |
| Week5 | 0.03 | [-0.08, 0.14] | 0.54 | .592 |
| GroupStress | 0.08 | [-0.03, 0.20] | 1.39 | .167 |
| BehaviorN | 0.01 | [-0.05, 0.06] | 0.30 | .766 |
| Week2 × GroupStress | -0.13 | [-0.29, 0.03] | -1.57 | .120 |
| Week3 × GroupStress | -0.10 | [-0.27, 0.08] | -1.09 | .279 |
| Week4 × GroupStress | 0.04 | [-0.13, 0.22] | 0.47 | .636 |
| Week5 × GroupStress | 0.00 | [-0.17, 0.17] | 0.02 | .981 |
| Norepinephrine, pg/mg | | | | |
| Intercept | 937.51 | [690.28, 1,184.75] | 7.43 | < .001 |
| Week2 | -163.89 | [-497.27, 169.48] | -0.96 | .338 |
| Week3 | -106.53 | [-439.91, 226.84] | -0.63 | .533 |
| Week4 | -197.99 | [-531.37, 135.38] | -1.16 | .248 |
| Week5 | 105.58 | [-227.80, 438.95] | 0.62 | .536 |
| GroupStress | -78.08 | [-411.45, 255.30] | -0.46 | .647 |
| BehaviorN | -48.15 | [-197.24, 100.94] | -0.63 | .528 |
| Week2 × GroupStress | 254.60 | [-216.86, 726.06] | 1.06 | .293 |
| Week3 × GroupStress | 463.23 | [-8.24, 934.69] | 1.93 | .057 |
| Week4 × GroupStress | 100.21 | [-371.25, 571.68] | 0.42 | .678 |
| Week5 × GroupStress | 310.81 | [-160.65, 782.28] | 1.29 | .200 |

Supplementary Table S8. Summary of statistical analyses for all differentially expressed genes in stress vs. control, fluoxetine vs. control or fluoxetine vs. stress groups, on the Negative Binomial (Gamma-Poisson) distribution performed by estimation of size factors, estimation of dispersion and negative binomial generalized linear models and Wald statistics using the DESeq function. P value and false discovery rate were set at 0.05. Genes in this table are listed as sorted by their p-adjusted value.

| Ensembl | external_gene_name | baseMean | log2FoldChange | lfcSE | Stat | pvalue | padj |
|---------------------------|--------------------|----------|----------------|----------|----------|----------|----------|
| Stress vs. Control | | | | | | | |
| ENSDARG00000093998 | si:ch73-7i4.2 | 164,8442 | 5,686818 | 0,620534 | 9,164391 | 4,98E-20 | 1,21E-15 |
| ENSDARG00000102639 | si:dkey-29d5.2 | 41,03763 | 6,214117 | 0,924045 | 6,724906 | 1,76E-11 | 2,14E-07 |
| ENSDARG00000079402 | tapbp.1 | 144,5193 | -1,78864 | 0,284994 | -6,27605 | 3,47E-10 | 2,82E-06 |
| ENSDARG00000094554 | si:ch73-7i4.1 | 37,6995 | 4,12461 | 0,750041 | 5,499177 | 3,82E-08 | 0,000232 |
| ENSDARG00000076586 | csf2rb | 50,70728 | -1,85704 | 0,341433 | -5,43895 | 5,36E-08 | 0,000248 |
| ENSDARG00000090890 | cmklr1 | 55,55607 | -1,7606 | 0,325129 | -5,41508 | 6,13E-08 | 0,000248 |
| ENSDARG00000100302 | si:dkey-237g15.2 | 108,2872 | -3,08287 | 0,601631 | -5,12419 | 2,99E-07 | 0,000891 |
| ENSDARG00000102835 | CABZ01021435.1 | 26,96331 | -1,9449 | 0,380925 | -5,10574 | 3,3E-07 | 0,000891 |
| ENSDARG00000079034 | zpax4 | 15,31746 | 2,711004 | 0,529375 | 5,121144 | 3,04E-07 | 0,000891 |
| ENSDARG00000090637 | myh6 | 13,27576 | -5,20513 | 1,062621 | -4,89839 | 9,66E-07 | 0,002138 |
| ENSDARG00000069839 | CU571382.1 | 29,63909 | -3,33594 | 0,680015 | -4,90569 | 9,31E-07 | 0,002138 |
| ENSDARG00000053973 | fetub | 6,957216 | 3,670704 | 0,752827 | 4,875896 | 1,08E-06 | 0,002197 |
| ENSDARG00000086374 | isg15 | 261,0382 | -3,83891 | 0,793292 | -4,83921 | 1,3E-06 | 0,002263 |
| ENSDARG00000104120 | LO018260.1 | 67,36825 | -1,21762 | 0,252712 | -4,8182 | 1,45E-06 | 0,002263 |
| ENSDARG00000077249 | gmip | 54,58877 | -1,06096 | 0,221001 | -4,80072 | 1,58E-06 | 0,002263 |
| ENSDARG00000002988 | tnnt2d | 40,15867 | 2,050141 | 0,426229 | 4,809951 | 1,51E-06 | 0,002263 |
| ENSDARG00000026979 | krt1-c5 | 299,3362 | 7,251248 | 1,510097 | 4,801841 | 1,57E-06 | 0,002263 |
| ENSDARG00000074136 | slc47a2.2 | 13,28693 | -4,82162 | 1,01405 | -4,75481 | 1,99E-06 | 0,002306 |
| ENSDARG00000014427 | mxe | 68,81475 | -4,23896 | 0,891577 | -4,75445 | 1,99E-06 | 0,002306 |
| ENSDARG00000094719 | CR318588.3 | 1227,035 | -4,16004 | 0,869977 | -4,78178 | 1,74E-06 | 0,002306 |
| ENSDARG00000078389 | ifi46 | 158,1358 | -2,49557 | 0,522744 | -4,77398 | 1,81E-06 | 0,002306 |
| ENSDARG00000059294 | marco | 174,3955 | -2,23722 | 0,476887 | -4,6913 | 2,71E-06 | 0,002872 |
| ENSDARG00000079997 | si:zfos-223e1.2 | 33,87397 | 1,598868 | 0,3406 | 4,694269 | 2,68E-06 | 0,002872 |
| ENSDARG00000087102 | si:ch1073-164k15.3 | 54,19928 | -4,9841 | 1,067979 | -4,66685 | 3,06E-06 | 0,003101 |
| ENSDARG00000055186 | ccr9a | 44,12408 | -2,80143 | 0,603577 | -4,64138 | 3,46E-06 | 0,003369 |
| ENSDARG00000094386 | adgrg4b | 49,28134 | 8,419412 | 1,829425 | 4,602218 | 4,18E-06 | 0,003913 |
| ENSDARG00000088251 | lgals17 | 195,6001 | -4,19997 | 0,922056 | -4,55501 | 5,24E-06 | 0,004605 |
| ENSDARG00000039490 | pitpnaa | 65,80556 | -1,27998 | 0,281611 | -4,54521 | 5,49E-06 | 0,004605 |
| ENSDARG00000100732 | si:dkeyp-93h6.1 | 24,14235 | 1,992828 | 0,437833 | 4,551574 | 5,32E-06 | 0,004605 |
| ENSDARG00000029720 | si:dkeyp-9d4.2 | 118,4261 | -2,75882 | 0,609126 | -4,52914 | 5,92E-06 | 0,004758 |
| ENSDARG00000010946 | cbsb | 1229,743 | -1,11274 | 0,24621 | -4,51949 | 6,2E-06 | 0,004758 |
| ENSDARG00000101585 | teca | 76,98249 | 6,34775 | 1,405135 | 4,517538 | 6,26E-06 | 0,004758 |
| ENSDARG00000010317 | gpr183a | 18,51935 | -1,57612 | 0,351277 | -4,48682 | 7,23E-06 | 0,005175 |
| ENSDARG00000067990 | myhz1.1 | 64,67868 | 2,700507 | 0,601157 | 4,492184 | 7,05E-06 | 0,005175 |
| ENSDARG00000010619 | themis | 14,19646 | -1,81447 | 0,40819 | -4,44516 | 8,78E-06 | 0,005937 |
| ENSDARG00000114894 | znf1026 | 19,7091 | -1,38193 | 0,310862 | -4,44548 | 8,77E-06 | 0,005937 |
| ENSDARG00000090600 | si:ch211-213a13.1 | 323,8362 | -3,22941 | 0,728271 | -4,43435 | 9,24E-06 | 0,006074 |
| ENSDARG00000117491 | CU855688.1 | 14,46722 | 1,922018 | 0,434193 | 4,426639 | 9,57E-06 | 0,00613 |

| | | | | | | | |
|--------------------|-------------------|----------|----------|----------|----------|----------|----------|
| ENSDARG00000092233 | vtg1 | 176,6857 | 2,944982 | 0,6664 | 4,419243 | 9,9E-06 | 0,006181 |
| ENSDARG00000028731 | stat4 | 34,94947 | -1,58575 | 0,36035 | -4,40058 | 1,08E-05 | 0,006568 |
| ENSDARG00000007467 | ifit10 | 18,52404 | -4,94187 | 1,137183 | -4,34571 | 1,39E-05 | 0,007947 |
| ENSDARG00000069961 | il21r.1 | 63,55553 | -1,29313 | 0,297719 | -4,34348 | 1,4E-05 | 0,007947 |
| ENSDARG00000032885 | si:ch211-226m7.4 | 33,89089 | 1,547943 | 0,356405 | 4,343211 | 1,4E-05 | 0,007947 |
| ENSDARG00000093214 | si:ch211-284e13.9 | 23,50924 | -1,66773 | 0,388949 | -4,2878 | 1,8E-05 | 0,009981 |
| ENSDARG00000095673 | si:dkey-79f11.8 | 30,39832 | -6,4794 | 1,529671 | -4,23581 | 2,28E-05 | 0,012115 |
| ENSDARG00000088831 | si:dkey-81j8.6 | 22,07982 | -1,99191 | 0,470394 | -4,23455 | 2,29E-05 | 0,012115 |
| ENSDARG00000101014 | slco1f4 | 4,985412 | 5,932084 | 1,402738 | 4,228934 | 2,35E-05 | 0,012158 |
| ENSDARG00000105266 | si:dkey-16p6.1 | 14,8571 | -2,59149 | 0,615033 | -4,21357 | 2,51E-05 | 0,012737 |
| ENSDARG00000075346 | tmem129 | 255,4415 | 0,505023 | 0,119985 | 4,209047 | 2,56E-05 | 0,012737 |
| ENSDARG00000074283 | inpp5d | 116,6038 | -1,11091 | 0,264307 | -4,2031 | 2,63E-05 | 0,012815 |
| ENSDARG00000095026 | si:dkey-58f10.14 | 10,72728 | -4,15513 | 0,994521 | -4,17802 | 2,94E-05 | 0,013357 |
| ENSDARG00000101728 | si:dkeyp-80d11.12 | 9,188694 | -3,03997 | 0,729765 | -4,16568 | 3,1E-05 | 0,013357 |
| ENSDARG00000071543 | si:dkey-42i9.7 | 28,76336 | -2,9514 | 0,706858 | -4,17538 | 2,97E-05 | 0,013357 |
| ENSDARG00000043475 | si:ch211-122h15.4 | 113,3422 | -1,67301 | 0,400194 | -4,1805 | 2,91E-05 | 0,013357 |
| ENSDARG00000071437 | ptprc | 343,6064 | -1,11075 | 0,266757 | -4,1639 | 3,13E-05 | 0,013357 |
| ENSDARG00000062049 | arhgap45b | 99,35305 | -0,92879 | 0,222678 | -4,17098 | 3,03E-05 | 0,013357 |
| ENSDARG00000055809 | vtg2 | 19,39724 | 5,828072 | 1,392504 | 4,185318 | 2,85E-05 | 0,013357 |
| ENSDARG00000056791 | pde6ga | 21,88924 | -3,64709 | 0,878431 | -4,15182 | 3,3E-05 | 0,01384 |
| ENSDARG00000074052 | si:ch211-281g13.5 | 61,93331 | -3,65391 | 0,884609 | -4,13054 | 3,62E-05 | 0,014438 |
| ENSDARG00000099949 | FP236551.1 | 48,90707 | -1,8141 | 0,439081 | -4,13158 | 3,6E-05 | 0,014438 |
| ENSDARG00000032631 | ltb4r | 39,66947 | -1,54528 | 0,373787 | -4,13413 | 3,56E-05 | 0,014438 |
| ENSDARG00000089463 | dhx58 | 63,537 | -3,29948 | 0,802559 | -4,1112 | 3,94E-05 | 0,01545 |
| ENSDARG00000041379 | si:ch211-245j22.3 | 53,2759 | -5,22288 | 1,276876 | -4,09036 | 4,31E-05 | 0,016638 |
| ENSDARG00000111309 | AL935126.2 | 37,11771 | 7,400761 | 1,812357 | 4,083502 | 4,44E-05 | 0,016869 |
| ENSDARG00000052288 | zmp:000000634 | 80,56334 | -5,23374 | 1,284563 | -4,07434 | 4,61E-05 | 0,017015 |
| ENSDARG00000077090 | si:ch211-127b11.1 | 16,06137 | 5,489022 | 1,34639 | 4,076845 | 4,57E-05 | 0,017015 |
| ENSDARG00000004459 | unc119.2 | 45,52201 | -4,57894 | 1,130001 | -4,05215 | 5,07E-05 | 0,017016 |
| ENSDARG00000054418 | ssuh2.2 | 16,49514 | -2,77854 | 0,685146 | -4,0554 | 5E-05 | 0,017016 |
| ENSDARG00000102525 | lck | 17,0159 | -1,98235 | 0,488948 | -4,05431 | 5,03E-05 | 0,017016 |
| ENSDARG00000019728 | bmpr1aa | 439,3845 | 0,627031 | 0,154914 | 4,047613 | 5,17E-05 | 0,017016 |
| ENSDARG00000058256 | draxin | 1407,05 | 0,665238 | 0,164239 | 4,050415 | 5,11E-05 | 0,017016 |
| ENSDARG00000094668 | si:ch211-51a19.5 | 85,66699 | 2,73115 | 0,671709 | 4,065971 | 4,78E-05 | 0,017016 |
| ENSDARG00000098315 | cyp1a | 20,05002 | 3,458075 | 0,854267 | 4,048005 | 5,17E-05 | 0,017016 |
| ENSDARG00000052165 | si:ch211-236k19.2 | 75,20497 | 5,488341 | 1,349347 | 4,067406 | 4,75E-05 | 0,017016 |
| ENSDARG00000074656 | ctss2.1 | 46,2542 | -1,63224 | 0,403898 | -4,04123 | 5,32E-05 | 0,017253 |
| ENSDARG00000015176 | ror1 | 39,3239 | -1,00205 | 0,248429 | -4,03355 | 5,49E-05 | 0,017592 |
| ENSDARG00000075389 | si:ch211-281g13.4 | 30,43102 | -3,7568 | 0,933473 | -4,02454 | 5,71E-05 | 0,018042 |
| ENSDARG00000007018 | ms4a17a.6 | 23,82854 | -1,55099 | 0,386569 | -4,0122 | 6,02E-05 | 0,018768 |
| ENSDARG00000035798 | gngt1 | 231,2607 | -4,58871 | 1,148379 | -3,99582 | 6,45E-05 | 0,019415 |
| ENSDARG00000004953 | mxh | 68,51614 | -3,91733 | 0,979392 | -3,99976 | 6,34E-05 | 0,019415 |
| ENSDARG00000076182 | stat1b | 200,0531 | -3,00857 | 0,754124 | -3,98949 | 6,62E-05 | 0,019415 |
| ENSDARG00000038095 | socs1a | 60,44625 | -1,72096 | 0,431249 | -3,99065 | 6,59E-05 | 0,019415 |
| ENSDARG00000088366 | zgc:77938 | 193,9505 | 1,411368 | 0,35339 | 3,993799 | 6,5E-05 | 0,019415 |
| ENSDARG00000075757 | gig2e | 11,43792 | -2,30678 | 0,578929 | -3,98457 | 6,76E-05 | 0,019586 |

| | | | | | | | |
|--------------------|--------------------|----------|----------|----------|----------|----------|----------|
| ENSDARG00000074546 | si:ch211-213a13.2 | 207,1771 | -4,26256 | 1,071408 | -3,97847 | 6,94E-05 | 0,019801 |
| ENSDARG00000104045 | tfr22 | 9,832313 | -2,26098 | 0,569042 | -3,97331 | 7,09E-05 | 0,019801 |
| ENSDARG00000015752 | zap70 | 32,19613 | -1,42027 | 0,357668 | -3,9709 | 7,16E-05 | 0,019801 |
| ENSDARG00000037408 | tbc1d10c | 41,53559 | -1,194 | 0,300553 | -3,97268 | 7,11E-05 | 0,019801 |
| ENSDARG00000052396 | pkz | 35,78193 | -2,68548 | 0,677851 | -3,96175 | 7,44E-05 | 0,020344 |
| ENSDARG00000010252 | jak3 | 44,89497 | -1,21599 | 0,307974 | -3,94835 | 7,87E-05 | 0,021278 |
| ENSDARG00000040942 | pnp6 | 782,434 | 0,691913 | 0,175374 | 3,945363 | 7,97E-05 | 0,021308 |
| ENSDARG00000092259 | si:dkey-211g8.5 | 3,67091 | -5,58819 | 1,422267 | -3,92907 | 8,53E-05 | 0,022002 |
| ENSDARG00000075072 | rpap1 | 258,9355 | -0,62954 | 0,160114 | -3,93184 | 8,43E-05 | 0,022002 |
| ENSDARG00000014196 | myl1 | 22,47509 | 2,590033 | 0,659487 | 3,927348 | 8,59E-05 | 0,022002 |
| ENSDARG00000045822 | tnnt2e | 97,31019 | 2,923894 | 0,744396 | 3,927875 | 8,57E-05 | 0,022002 |
| ENSDARG00000101071 | si:dkeyp-80d11.14 | 9,692705 | -1,69541 | 0,43224 | -3,92239 | 8,77E-05 | 0,022226 |
| ENSDARG00000093748 | si:ch211-217k17.11 | 74,89433 | -3,07385 | 0,786411 | -3,90871 | 9,28E-05 | 0,023042 |
| ENSDARG00000037358 | polr3e | 639,91 | 0,740317 | 0,189372 | 3,909328 | 9,26E-05 | 0,023042 |
| ENSDARG00000105364 | si:ch73-223f5.1 | 249,9613 | -2,25547 | 0,578322 | -3,90002 | 9,62E-05 | 0,023602 |
| ENSDARG00000055730 | trim35-29 | 26,2314 | 2,224615 | 0,570704 | 3,89802 | 9,7E-05 | 0,023602 |
| ENSDARG00000076158 | zgc:165583 | 14,77398 | -1,73106 | 0,444598 | -3,89354 | 9,88E-05 | 0,023804 |
| ENSDARG00000098189 | si:dkey-16p6.1 | 21,01967 | -2,0213 | 0,520049 | -3,88674 | 0,000102 | 0,024005 |
| ENSDARG00000075504 | si:dkey-40c23.2 | 39,2451 | -1,77002 | 0,455386 | -3,88687 | 0,000102 | 0,024005 |
| ENSDARG00000117508 | CU459056.2 | 31,31827 | -2,81318 | 0,726197 | -3,87385 | 0,000107 | 0,025048 |
| ENSDARG00000104450 | CR855996.2 | 18,79987 | 2,993049 | 0,773054 | 3,871719 | 0,000108 | 0,025048 |
| ENSDARG00000092191 | CR318588.1 | 1186,549 | -3,8714 | 1,002492 | -3,86178 | 0,000113 | 0,025602 |
| ENSDARG00000040582 | C18H3orf33 | 96,04662 | 0,956905 | 0,247762 | 3,862198 | 0,000112 | 0,025602 |
| ENSDARG00000058774 | CABZ01053221.1 | 6,751038 | -2,13749 | 0,554449 | -3,85516 | 0,000116 | 0,02606 |
| ENSDARG00000077130 | bcl10 | 19,27022 | -1,44581 | 0,375445 | -3,85093 | 0,000118 | 0,026272 |
| ENSDARG00000025428 | soes3a | 319,8547 | -2,28392 | 0,593862 | -3,84587 | 0,00012 | 0,026576 |
| ENSDARG00000061177 | mov10b.1 | 67,60348 | -2,23373 | 0,582393 | -3,83543 | 0,000125 | 0,027056 |
| ENSDARG00000044235 | BX005421.1 | 11,77669 | -1,87999 | 0,490235 | -3,83487 | 0,000126 | 0,027056 |
| ENSDARG00000022183 | gstol | 561,16 | 0,791405 | 0,206245 | 3,837212 | 0,000124 | 0,027056 |
| ENSDARG00000070028 | tmem41aa | 294,3783 | -0,52064 | 0,136132 | -3,82454 | 0,000131 | 0,027969 |
| ENSDARG00000086391 | cald1b | 29,47612 | 1,741375 | 0,455576 | 3,822362 | 0,000132 | 0,027971 |
| ENSDARG00000013855 | slc12a3 | 25,84152 | 2,833511 | 0,741834 | 3,819602 | 0,000134 | 0,028042 |
| ENSDARG00000100968 | si:ch211-1a19.3 | 127,6878 | -1,3544 | 0,355749 | -3,80717 | 0,000141 | 0,029237 |
| ENSDARG00000097559 | cyp8b3 | 23,46184 | -3,1911 | 0,83928 | -3,80219 | 0,000143 | 0,02958 |
| ENSDARG00000093753 | BX004774.2 | 193,7659 | -3,35418 | 0,884297 | -3,79305 | 0,000149 | 0,030432 |
| ENSDARG00000013655 | tpd5212b | 1755,256 | 0,396047 | 0,104678 | 3,783498 | 0,000155 | 0,031102 |
| ENSDARG00000099860 | pkmb | 19,15483 | 1,985092 | 0,52447 | 3,784949 | 0,000154 | 0,031102 |
| ENSDARG00000032584 | thnsl2 | 58,5869 | 1,312257 | 0,347211 | 3,77942 | 0,000157 | 0,031356 |
| ENSDARG00000112454 | FO744833.2 | 250,7418 | -1,06081 | 0,281449 | -3,7691 | 0,000164 | 0,032415 |
| ENSDARG00000039243 | zgc:152791 | 379,5849 | -4,08968 | 1,08629 | -3,76482 | 0,000167 | 0,032449 |
| ENSDARG00000107526 | smkr1 | 91,23716 | 1,22454 | 0,325166 | 3,765891 | 0,000166 | 0,032449 |
| ENSDARG00000038288 | cd151 | 53,99511 | 1,22684 | 0,326066 | 3,762555 | 0,000168 | 0,032484 |
| ENSDARG00000101169 | grap2b | 69,45649 | -1,34499 | 0,357704 | -3,76006 | 0,00017 | 0,032551 |
| ENSDARG00000068939 | xaf1 | 80,99448 | -2,10235 | 0,5609 | -3,74818 | 0,000178 | 0,033866 |
| ENSDARG00000043483 | otx5 | 21,80288 | -4,75563 | 1,270297 | -3,74372 | 0,000181 | 0,033915 |
| ENSDARG00000078731 | si:dkey-85k7.12 | 46,23873 | -3,24038 | 0,865637 | -3,74335 | 0,000182 | 0,033915 |

| | | | | | | | |
|--------------------|-------------------|----------|----------|----------|----------|----------|----------|
| ENSDARG00000100900 | si:ch211-183d5.2 | 90,99566 | -2,64398 | 0,70701 | -3,73967 | 0,000184 | 0,033915 |
| ENSDARG00000092653 | si:dkey-1h24.6 | 10,56826 | -1,46668 | 0,391992 | -3,7416 | 0,000183 | 0,033915 |
| ENSDARG00000002682 | tbcela | 1466,567 | 0,437677 | 0,117083 | 3,738187 | 0,000185 | 0,033915 |
| ENSDARG00000092126 | vtg5 | 23,70013 | 3,134181 | 0,842453 | 3,720305 | 0,000199 | 0,036138 |
| ENSDARG00000101272 | si:dkey-29j8.1 | 6,759197 | -1,94503 | 0,523401 | -3,71615 | 0,000202 | 0,036465 |
| ENSDARG00000055159 | cyp27a1.4 | 191,0922 | 0,818813 | 0,220705 | 3,709983 | 0,000207 | 0,036863 |
| ENSDARG00000053323 | zgc:112285 | 19,59111 | 1,085756 | 0,292827 | 3,707837 | 0,000209 | 0,036863 |
| ENSDARG00000097580 | BX663519.1 | 55,41507 | 2,045346 | 0,55146 | 3,708969 | 0,000208 | 0,036863 |
| ENSDARG00000089185 | si:ch73-264i18.2 | 2,574693 | 5,23719 | 1,41348 | 3,705175 | 0,000211 | 0,036985 |
| ENSDARG00000032932 | cnksr1 | 19,13048 | -1,15229 | 0,311167 | -3,70313 | 0,000213 | 0,037018 |
| ENSDARG00000054610 | coro1a | 158,7542 | -1,13353 | 0,306657 | -3,69639 | 0,000219 | 0,037478 |
| ENSDARG00000034063 | unm_sa911 | 124,8442 | -1,01276 | 0,273941 | -3,697 | 0,000218 | 0,037478 |
| ENSDARG00000090730 | cfbl | 23,55705 | -1,94248 | 0,527028 | -3,68572 | 0,000228 | 0,038276 |
| ENSDARG00000089227 | si:ch211-91p5.3 | 148,7863 | -1,22865 | 0,333224 | -3,68714 | 0,000227 | 0,038276 |
| ENSDARG00000004954 | grna | 435,3453 | -0,97673 | 0,264828 | -3,68817 | 0,000226 | 0,038276 |
| ENSDARG00000008592 | mtmr8 | 211,84 | -1,80008 | 0,489257 | -3,67922 | 0,000234 | 0,038995 |
| ENSDARG00000074501 | tnip2 | 14,95865 | -1,8318 | 0,498515 | -3,67452 | 0,000238 | 0,039451 |
| ENSDARG00000112831 | znf1116 | 5,616213 | -3,68212 | 1,007437 | -3,65494 | 0,000257 | 0,040309 |
| ENSDARG00000034095 | si:dkey-59111.10 | 4,273366 | -3,45926 | 0,947606 | -3,65053 | 0,000262 | 0,040309 |
| ENSDARG00000113386 | LO018432.1 | 13,70658 | -3,40887 | 0,933373 | -3,6522 | 0,00026 | 0,040309 |
| ENSDARG00000093254 | znf569l | 22,27115 | -1,74352 | 0,476823 | -3,65653 | 0,000256 | 0,040309 |
| ENSDARG00000002165 | psme1 | 196,5018 | -1,24669 | 0,340793 | -3,6582 | 0,000254 | 0,040309 |
| ENSDARG00000094451 | cfp | 291,775 | -1,13416 | 0,309322 | -3,66658 | 0,000246 | 0,040309 |
| ENSDARG00000094854 | ms4a17a.9 | 23,93016 | -1,12734 | 0,308705 | -3,65183 | 0,00026 | 0,040309 |
| ENSDARG00000071558 | fbli1 | 86,34791 | 0,791259 | 0,216127 | 3,661085 | 0,000251 | 0,040309 |
| ENSDARG00000096045 | si:ch73-263o4.4 | 21,07568 | 1,864121 | 0,510054 | 3,654755 | 0,000257 | 0,040309 |
| ENSDARG00000087641 | cdh26.2 | 27,49433 | 2,062629 | 0,563345 | 3,661399 | 0,000251 | 0,040309 |
| ENSDARG00000045592 | tnni2a.1 | 41,53237 | 4,136382 | 1,131927 | 3,654282 | 0,000258 | 0,040309 |
| ENSDARG00000092159 | CR788249.1 | 20,92327 | -4,21296 | 1,157248 | -3,6405 | 0,000272 | 0,041537 |
| ENSDARG00000039512 | ap1m3 | 51,50422 | -1,22567 | 0,336763 | -3,63957 | 0,000273 | 0,041537 |
| ENSDARG00000096355 | ighv1-4 | 116,5287 | -4,07637 | 1,120754 | -3,63717 | 0,000276 | 0,041666 |
| ENSDARG00000008306 | rdh5 | 41,4861 | -3,83153 | 1,056286 | -3,62736 | 0,000286 | 0,04275 |
| ENSDARG00000100434 | znf1091 | 28,42767 | -3,03531 | 0,83643 | -3,62889 | 0,000285 | 0,04275 |
| ENSDARG00000052223 | rcvma | 24,89004 | -4,98773 | 1,38359 | -3,60492 | 0,000312 | 0,043175 |
| ENSDARG00000100568 | si:ch211-209j12.3 | 5,64605 | -3,59469 | 0,996871 | -3,60598 | 0,000311 | 0,043175 |
| ENSDARG00000002696 | gnb3b | 50,1038 | -2,72007 | 0,754059 | -3,60724 | 0,000309 | 0,043175 |
| ENSDARG00000004952 | rsad2 | 151,1438 | -2,29699 | 0,636882 | -3,60662 | 0,00031 | 0,043175 |
| ENSDARG00000098515 | si:dkey-16p6.1 | 54,17549 | -1,69489 | 0,469968 | -3,60639 | 0,00031 | 0,043175 |
| ENSDARG00000100669 | si:dkey-61p9.9 | 18,42742 | -1,47296 | 0,408158 | -3,60879 | 0,000308 | 0,043175 |
| ENSDARG00000114991 | tmem14cb | 32,63878 | -1,22506 | 0,338416 | -3,61999 | 0,000295 | 0,043175 |
| ENSDARG00000069774 | flot2b | 1183,238 | 0,363745 | 0,100632 | 3,614625 | 0,000301 | 0,043175 |
| ENSDARG00000015482 | zgc:113518 | 197,057 | 0,514276 | 0,142076 | 3,619716 | 0,000295 | 0,043175 |
| ENSDARG00000075599 | cdc25d | 51,14493 | 0,687367 | 0,190245 | 3,613054 | 0,000303 | 0,043175 |
| ENSDARG00000094901 | abcc6b.2 | 17,71361 | 1,093126 | 0,301822 | 3,621754 | 0,000293 | 0,043175 |
| ENSDARG00000019128 | tpm4b | 69,61131 | 1,403176 | 0,38894 | 3,607694 | 0,000309 | 0,043175 |
| ENSDARG00000095024 | si:dkeyp-68b7.10 | 5,475087 | 2,323612 | 0,642833 | 3,614645 | 0,000301 | 0,043175 |

| | | | | | | | |
|-------------------------------|--------------------|----------|----------|----------|----------|----------|----------|
| ENSDARG00000044612 | c1qb | 41,35639 | -1,48744 | 0,412887 | -3,60255 | 0,000315 | 0,043325 |
| ENSDARG00000101309 | si:ch73-100l22.3 | 227,2183 | 0,752427 | 0,209258 | 3,595699 | 0,000324 | 0,044232 |
| ENSDARG00000101675 | zgc:123107 | 60,63829 | -1,22681 | 0,341577 | -3,5916 | 0,000329 | 0,044433 |
| ENSDARG00000020610 | tnnt2a | 13,70478 | 2,009186 | 0,559411 | 3,59161 | 0,000329 | 0,044433 |
| ENSDARG00000005713 | ethe1 | 180,6208 | 0,715788 | 0,200044 | 3,578154 | 0,000346 | 0,046016 |
| ENSDARG00000098046 | FP017161.1 | 196,3582 | 0,871499 | 0,243536 | 3,578517 | 0,000346 | 0,046016 |
| ENSDARG00000098811 | LO018021.1 | 38,82198 | 0,879947 | 0,245746 | 3,580713 | 0,000343 | 0,046016 |
| ENSDARG00000054340 | sla1a | 12,8555 | -1,84624 | 0,517082 | -3,5705 | 0,000356 | 0,047124 |
| ENSDARG00000078618 | inpp5kb | 54,3152 | -2,24734 | 0,629697 | -3,56892 | 0,000358 | 0,047153 |
| ENSDARG00000089930 | iqce | 451,2363 | 0,846778 | 0,237392 | 3,567004 | 0,000361 | 0,047244 |
| ENSDARG00000044199 | gnat1 | 271,0448 | -4,22288 | 1,186217 | -3,55995 | 0,000371 | 0,048014 |
| ENSDARG00000103551 | rnf213b | 78,05034 | -2,76741 | 0,777137 | -3,56103 | 0,000369 | 0,048014 |
| ENSDARG00000078130 | CR391986.1 | 68,27406 | 0,555449 | 0,156091 | 3,558495 | 0,000373 | 0,048026 |
| ENSDARG00000091627 | si:dkey-271j15.3 | 18,75689 | -2,85533 | 0,802833 | -3,55657 | 0,000376 | 0,048046 |
| ENSDARG00000100420 | tpcn2 | 38,46233 | -2,2763 | 0,640198 | -3,55562 | 0,000377 | 0,048046 |
| ENSDARG00000103720 | zgc:162730 | 428,5616 | -1,05731 | 0,297686 | -3,55178 | 0,000383 | 0,048499 |
| ENSDARG00000034160 | slc4a1ap | 852,5459 | 0,356273 | 0,100466 | 3,546204 | 0,000391 | 0,049026 |
| ENSDARG00000038941 | ppp1r1c | 914,9612 | 0,947675 | 0,26721 | 3,546548 | 0,00039 | 0,049026 |
| ENSDARG00000090977 | ifit12 | 8,278224 | -2,10441 | 0,593758 | -3,54422 | 0,000394 | 0,049144 |
| ENSDARG00000086848 | atad3 | 94,54343 | -0,72335 | 0,204181 | -3,5427 | 0,000396 | 0,049174 |
| Fluoxetine vs. Control | | | | | | | |
| ENSDARG00000093998 | si:ch73-7i4.2 | 164,8442 | 5,23191 | 0,601678 | 8,695536 | 3,45E-18 | 7,63E-14 |
| ENSDARG00000075757 | gig2e | 11,43792 | -3,85335 | 0,635052 | -6,06777 | 1,3E-09 | 1,43E-05 |
| ENSDARG00000102639 | si:dkey-29d5.2 | 41,03763 | 5,294999 | 0,903836 | 5,858365 | 4,67E-09 | 3,44E-05 |
| ENSDARG00000069839 | CU571382.1 | 29,63909 | -3,57225 | 0,656588 | -5,44063 | 5,31E-08 | 0,000276 |
| ENSDARG00000078389 | ifi46 | 158,1358 | -2,7274 | 0,50396 | -5,41194 | 6,23E-08 | 0,000276 |
| ENSDARG00000087102 | si:ch1073-164k15.3 | 54,19928 | -5,37584 | 1,034098 | -5,19858 | 2,01E-07 | 0,00074 |
| ENSDARG00000026979 | krt1-c5 | 299,3362 | 7,266663 | 1,457883 | 4,984394 | 6,22E-07 | 0,001963 |
| ENSDARG00000090600 | si:ch211-213a13.1 | 323,8362 | -3,46337 | 0,701894 | -4,93433 | 8,04E-07 | 0,002101 |
| ENSDARG00000029720 | si:dkeyp-9d4.2 | 118,4261 | -2,8883 | 0,586773 | -4,92235 | 8,55E-07 | 0,002101 |
| ENSDARG00000092919 | zp3c | 4,913544 | -5,64865 | 1,157449 | -4,88026 | 1,06E-06 | 0,002342 |
| ENSDARG00000088251 | lgals17 | 195,6001 | -4,28668 | 0,888117 | -4,8267 | 1,39E-06 | 0,00279 |
| ENSDARG00000074052 | si:ch211-281g13.5 | 61,93331 | -3,9522 | 0,853709 | -4,62945 | 3,67E-06 | 0,00548 |
| ENSDARG00000094719 | CR318588.3 | 1227,035 | -3,8692 | 0,838033 | -4,617 | 3,89E-06 | 0,00548 |
| ENSDARG00000092653 | si:dkey-1h24.6 | 10,56826 | -1,78926 | 0,384799 | -4,64985 | 3,32E-06 | 0,00548 |
| ENSDARG00000074466 | gdpd3a | 29,9061 | 1,20471 | 0,261146 | 4,613172 | 3,97E-06 | 0,00548 |
| ENSDARG00000111309 | AL935126.2 | 37,11771 | 8,144139 | 1,759393 | 4,628947 | 3,68E-06 | 0,00548 |
| ENSDARG00000007018 | ms4a17a.6 | 23,82854 | -1,67663 | 0,371835 | -4,50908 | 6,51E-06 | 0,00805 |
| ENSDARG00000010252 | jak3 | 44,89497 | -1,33266 | 0,296398 | -4,49619 | 6,92E-06 | 0,00805 |
| ENSDARG00000052165 | si:ch211-236k19.2 | 75,20497 | 5,87199 | 1,304001 | 4,503057 | 6,7E-06 | 0,00805 |
| ENSDARG00000019601 | col12a1b | 137,9121 | -3,57917 | 0,814411 | -4,3948 | 1,11E-05 | 0,011672 |
| ENSDARG00000076158 | zgc:165583 | 14,77398 | -1,88427 | 0,428078 | -4,40171 | 1,07E-05 | 0,011672 |
| ENSDARG00000095309 | si:dkey-79f11.9 | 36,29543 | -4,0224 | 0,920755 | -4,36859 | 1,25E-05 | 0,01202 |
| ENSDARG00000087641 | cdh26.2 | 27,49433 | 2,372439 | 0,542722 | 4,371371 | 1,23E-05 | 0,01202 |
| ENSDARG00000008592 | mtmr8 | 211,84 | -2,03965 | 0,471631 | -4,32466 | 1,53E-05 | 0,012831 |
| ENSDARG00000012881 | slc4a1a | 147,5154 | -1,46805 | 0,339068 | -4,32966 | 1,49E-05 | 0,012831 |

| | | | | | | | |
|------------------------------|-------------------|----------|----------|----------|----------|----------|----------|
| ENSDARG00000078193 | si:ch211-67e16.3 | 11,84568 | -1,37999 | 0,317853 | -4,34161 | 1,41E-05 | 0,012831 |
| ENSDARG00000094554 | si:ch73-7i4.1 | 37,6995 | 3,148321 | 0,728938 | 4,319054 | 1,57E-05 | 0,012831 |
| ENSDARG00000095026 | si:dkey-58f10.14 | 10,72728 | -4,04741 | 0,938916 | -4,31072 | 1,63E-05 | 0,012848 |
| ENSDARG00000024032 | coch | 283,3135 | -3,06525 | 0,713951 | -4,29337 | 1,76E-05 | 0,012969 |
| ENSDARG00000079402 | tapbp.1 | 144,5193 | -1,1655 | 0,271111 | -4,299 | 1,72E-05 | 0,012969 |
| ENSDARG00000086374 | isg15 | 261,0382 | -3,21871 | 0,762464 | -4,22146 | 2,43E-05 | 0,016892 |
| ENSDARG00000074656 | ctss2.1 | 46,2542 | -1,63579 | 0,387645 | -4,21982 | 2,45E-05 | 0,016892 |
| ENSDARG00000090267 | CU062628.1 | 16,30255 | 2,569695 | 0,610233 | 4,211005 | 2,54E-05 | 0,017032 |
| ENSDARG00000034473 | ttyh3a | 1828,15 | -0,34355 | 0,082096 | -4,18477 | 2,85E-05 | 0,018561 |
| ENSDARG00000105364 | si:ch73-223f5.1 | 249,9613 | -2,32072 | 0,557109 | -4,16566 | 3,1E-05 | 0,01961 |
| ENSDARG00000022183 | gstol | 561,16 | 0,825369 | 0,198708 | 4,153682 | 3,27E-05 | 0,020092 |
| ENSDARG00000040282 | zgc:92590 | 58,28274 | 3,142379 | 0,764166 | 4,112165 | 3,92E-05 | 0,02342 |
| ENSDARG00000102835 | CABZ01021435.1 | 26,96331 | -1,43292 | 0,353846 | -4,04957 | 5,13E-05 | 0,029853 |
| ENSDARG00000039243 | zgc:152791 | 379,5849 | -4,19111 | 1,046639 | -4,00435 | 6,22E-05 | 0,034371 |
| ENSDARG00000076586 | csf2rb | 50,70728 | -1,28586 | 0,320894 | -4,00713 | 6,15E-05 | 0,034371 |
| ENSDARG00000089227 | si:ch211-91p5.3 | 148,7863 | -1,27266 | 0,320772 | -3,96749 | 7,26E-05 | 0,039165 |
| ENSDARG00000010729 | CABZ01073795.1 | 515,0924 | -3,24934 | 0,832737 | -3,902 | 9,54E-05 | 0,04894 |
| ENSDARG00000076182 | stat1b | 200,0531 | -2,82559 | 0,725852 | -3,89279 | 9,91E-05 | 0,04894 |
| ENSDARG00000070132 | aste1a | 46,78711 | -2,44764 | 0,63025 | -3,8836 | 0,000103 | 0,04894 |
| ENSDARG00000010619 | themis | 14,19646 | -1,45562 | 0,375914 | -3,87223 | 0,000108 | 0,04894 |
| ENSDARG00000040942 | pnp6 | 782,434 | 0,657659 | 0,169004 | 3,891394 | 9,97E-05 | 0,04894 |
| ENSDARG00000092062 | BX511123.2 | 74,96263 | 0,881983 | 0,227854 | 3,87082 | 0,000108 | 0,04894 |
| ENSDARG00000056248 | si:dkey-183i3.5 | 63,86707 | 2,962784 | 0,764435 | 3,875781 | 0,000106 | 0,04894 |
| ENSDARG00000101585 | tecra | 76,98249 | 5,307561 | 1,359124 | 3,905133 | 9,42E-05 | 0,04894 |
| Fluoxetine vs. Stress | | | | | | | |
| ENSDARG00000100302 | si:dkey-237g15.2 | 108,2872 | 2,90793 | 0,581199 | 5,003329 | 5,63E-07 | 0,013086 |
| ENSDARG00000100434 | znf1091 | 28,42767 | 3,918893 | 0,807863 | 4,850939 | 1,23E-06 | 0,014269 |
| ENSDARG00000094386 | adgrg4b | 49,28134 | -7,56984 | 1,691682 | -4,47474 | 7,65E-06 | 0,028179 |
| ENSDARG00000102558 | pde6ha | 146,3818 | 2,761691 | 0,621272 | 4,445218 | 8,78E-06 | 0,028179 |
| ENSDARG00000020696 | gnb3b | 50,1038 | 3,23506 | 0,727714 | 4,445509 | 8,77E-06 | 0,028179 |
| ENSDARG00000056511 | arr3a | 96,37119 | 3,967655 | 0,888263 | 4,466758 | 7,94E-06 | 0,028179 |
| ENSDARG00000035798 | gngt1 | 231,2607 | 4,899159 | 1,107504 | 4,423605 | 9,71E-06 | 0,028179 |
| ENSDARG00000104919 | si:ch211-153b23.3 | 15,75144 | 6,587543 | 1,444016 | 4,561959 | 5,07E-06 | 0,028179 |
| ENSDARG00000052057 | pcolceb | 37,76886 | -3,10023 | 0,725539 | -4,27301 | 1,93E-05 | 0,043741 |
| ENSDARG00000059163 | rbp3 | 153,2547 | 3,47854 | 0,809138 | 4,299067 | 1,72E-05 | 0,043741 |
| ENSDARG00000012610 | saga | 87,58627 | 5,196321 | 1,220649 | 4,257013 | 2,07E-05 | 0,043741 |
| ENSDARG00000099860 | pkmb | 19,15483 | -2,12218 | 0,509276 | -4,16705 | 3,09E-05 | 0,049546 |
| ENSDARG00000057648 | dnttip2 | 254,251 | 0,536119 | 0,129562 | 4,137921 | 3,5E-05 | 0,049546 |
| ENSDARG00000095801 | BX649485.2 | 68,99263 | 2,90827 | 0,702904 | 4,137506 | 3,51E-05 | 0,049546 |
| ENSDARG00000008306 | rdh5 | 41,4861 | 4,202817 | 1,020871 | 4,116895 | 3,84E-05 | 0,049546 |
| ENSDARG00000041379 | si:ch211-245j22.3 | 53,2759 | 5,096952 | 1,235552 | 4,125244 | 3,7E-05 | 0,049546 |
| ENSDARG00000043483 | otx5 | 21,80288 | 5,151354 | 1,233783 | 4,175251 | 2,98E-05 | 0,049546 |
| ENSDARG00000105096 | si:ch1073-67j19.1 | 13,8963 | 5,255277 | 1,261485 | 4,165945 | 3,1E-05 | 0,049546 |

Supplementary Table S9. Statistical data for pathways enriched in stress vs. control, fluoxetine vs. control or fluoxetine vs. stress groups as in Supplementary Table S1. The KEGG- and GO-pathways enrichment analysis was performed on normalized and log2-transformed counts by general applicable gene set enrichment for pathway analysis (GAGE) package⁴, using two-tailed t-test for group comparison of differential expression of gene sets. False discovery rate cutoffs were set at 0.05 for KEGG pathways and 0.01 for GO pathways. The p value for GO pathways was reduced to 0.01 because it has more pathways than KEGG (~40 000 vs. ~500), and 0.05 FDR for GO already results in the large amount of significantly altered pathways, hence complicating our intended focus here on the most significant (e.g., most strongly affected) pathways instead. p.geomean – geometric mean of the individual p-values from multiple single array based gene set tests, stat.mean - mean of the individual statistics from multiple single array based gene set tests.

| Pathway | p.geomean | stat.mean | p.val | q.val | set.size |
|---|-----------|-----------|----------|----------|----------|
| Stress vs. Control upregulated | | | | | |
| GO | | | | | |
| GO:0043292 contractile fiber | 5,7E-11 | 6,756234 | 5,7E-11 | 9,17E-08 | 134 |
| GO:0030016 myofibril | 6,37E-11 | 6,73993 | 6,37E-11 | 9,17E-08 | 133 |
| GO:0044449 contractile fiber part | 7,13E-11 | 6,723342 | 7,13E-11 | 9,17E-08 | 132 |
| GO:0030017 sarcomere | 7,97E-11 | 6,707025 | 7,97E-11 | 9,17E-08 | 131 |
| GO:0005865 striated muscle thin filament | 3,3E-10 | 6,94235 | 3,3E-10 | 2,53E-07 | 54 |
| GO:0036379 myofilament | 3,3E-10 | 6,94235 | 3,3E-10 | 2,53E-07 | 54 |
| GO:0003735 structural constituent of ribosome | 6,6E-10 | 6,388184 | 6,6E-10 | 4,34E-07 | 152 |
| GO:0099080 supramolecular complex | 1,24E-09 | 6,0308 | 1,24E-09 | 6,32E-07 | 435 |
| GO:0099081 supramolecular polymer | 1,24E-09 | 6,0308 | 1,24E-09 | 6,32E-07 | 435 |
| GO:0099512 supramolecular fiber | 1,83E-09 | 5,963975 | 1,83E-09 | 8,44E-07 | 434 |
| GO:0005861 troponin complex | 8,57E-09 | 6,964295 | 8,57E-09 | 3,51E-06 | 25 |
| GO:0044391 ribosomal subunit | 9,15E-09 | 5,901812 | 9,15E-09 | 3,51E-06 | 142 |
| GO:0005840 ribosome | 2,03E-08 | 5,663013 | 2,03E-08 | 7,18E-06 | 179 |
| GO:0003009 skeletal muscle contraction | 2,56E-08 | 6,543129 | 2,56E-08 | 8,42E-06 | 28 |
| GO:0050879 multicellular organismal movement | 4,14E-08 | 6,29183 | 4,14E-08 | 1,19E-05 | 31 |
| GO:0050881 musculoskeletal movement | 4,14E-08 | 6,29183 | 4,14E-08 | 1,19E-05 | 31 |
| GO:0006397 mRNA processing | 9,51E-08 | 5,287186 | 9,51E-08 | 2,58E-05 | 292 |
| GO:0009199 ribonucleoside triphosphate metabolic process | 1,12E-07 | 5,307604 | 1,12E-07 | 2,87E-05 | 143 |
| GO:0009205 purine ribonucleoside triphosphate metabolic process | 1,39E-07 | 5,273186 | 1,39E-07 | 3,37E-05 | 134 |
| GO:0009144 purine nucleoside triphosphate metabolic process | 1,58E-07 | 5,245025 | 1,58E-07 | 3,64E-05 | 136 |
| GO:0006936 muscle contraction | 1,9E-07 | 5,267732 | 1,9E-07 | 4,17E-05 | 117 |
| GO:0098798 mitochondrial protein complex | 3,07E-07 | 5,097474 | 3,07E-07 | 6,42E-05 | 198 |
| GO:0003012 muscle system process | 3,95E-07 | 5,101369 | 3,95E-07 | 7,9E-05 | 124 |
| GO:0009141 nucleoside triphosphate metabolic process | 4,26E-07 | 5,027818 | 4,26E-07 | 8,18E-05 | 152 |
| GO:0044455 mitochondrial membrane part | 6,54E-07 | 4,952215 | 6,54E-07 | 0,00012 | 163 |
| GO:0044445 cytosolic part | 1,05E-06 | 4,843757 | 1,05E-06 | 0,000186 | 159 |
| GO:0008380 RNA splicing | 2,22E-06 | 4,653209 | 2,22E-06 | 0,000379 | 237 |
| GO:0046034 ATP metabolic process | 3,84E-06 | 4,57801 | 3,84E-06 | 0,000631 | 117 |
| GO:0022626 cytosolic ribosome | 4,99E-06 | 4,59203 | 4,99E-06 | 0,000792 | 87 |
| GO:0070469 respiratory chain | 7,28E-06 | 4,524333 | 7,28E-06 | 0,001117 | 75 |
| GO:0030018 Z disc | 8,43E-06 | 4,457722 | 8,43E-06 | 0,001252 | 74 |
| GO:0006941 striated muscle contraction | 8,99E-06 | 4,583173 | 8,99E-06 | 0,001294 | 50 |

| | | | | | |
|--|----------|----------|----------|----------|-----|
| GO:0006412 translation | 9,52E-06 | 4,3053 | 9,52E-06 | 0,001328 | 412 |
| GO:0098800 inner mitochondrial membrane protein complex | 1,04E-05 | 4,375027 | 1,04E-05 | 0,001408 | 109 |
| GO:0031674 I band | 1,09E-05 | 4,381794 | 1,09E-05 | 0,001431 | 83 |
| GO:0044427 chromosomal part | 1,14E-05 | 4,259254 | 1,14E-05 | 0,001462 | 461 |
| GO:0016071 mRNA metabolic process | 1,19E-05 | 4,253874 | 1,19E-05 | 0,001484 | 391 |
| GO:0043043 peptide biosynthetic process | 1,4E-05 | 4,216929 | 1,4E-05 | 0,001692 | 417 |
| GO:0015934 large ribosomal subunit | 1,43E-05 | 4,383207 | 1,43E-05 | 0,001692 | 83 |
| GO:0009123 nucleoside monophosphate metabolic process | 1,58E-05 | 4,221616 | 1,58E-05 | 0,001822 | 162 |
| GO:0000003 reproduction | 1,65E-05 | 4,189676 | 1,65E-05 | 0,001855 | 255 |
| GO:0006518 peptide metabolic process | 1,71E-05 | 4,164812 | 1,71E-05 | 0,001873 | 491 |
| GO:0005179 hormone activity | 2E-05 | 4,189538 | 2E-05 | 0,002146 | 115 |
| GO:0017144 drug metabolic process | 2,38E-05 | 4,091858 | 2,38E-05 | 0,002436 | 365 |
| GO:0009161 ribonucleoside monophosphate metabolic process | 2,38E-05 | 4,124877 | 2,38E-05 | 0,002436 | 158 |
| GO:0006091 generation of precursor metabolites and energy | 2,44E-05 | 4,113422 | 2,44E-05 | 0,002439 | 176 |
| GO:0098803 respiratory chain complex | 2,62E-05 | 4,224879 | 2,62E-05 | 0,002517 | 67 |
| GO:0000375 RNA splicing, via transesterification reactions | 2,73E-05 | 4,09329 | 2,73E-05 | 0,002517 | 187 |
| GO:0000377 RNA splicing, via transesterification reactions | 2,73E-05 | 4,09329 | 2,73E-05 | 0,002517 | 187 |
| GO:0000398 mRNA splicing, via spliceosome | 2,73E-05 | 4,09329 | 2,73E-05 | 0,002517 | 187 |
| GO:0005746 mitochondrial respiratory chain | 2,8E-05 | 4,204058 | 2,8E-05 | 0,002523 | 66 |
| GO:0022414 reproductive process | 2,85E-05 | 4,060517 | 2,85E-05 | 0,002523 | 251 |
| GO:0009126 purine nucleoside monophosphate metabolic process | 3,03E-05 | 4,070776 | 3,03E-05 | 0,002585 | 145 |
| GO:0009167 purine ribonucleoside monophosphate metabolic process | 3,03E-05 | 4,070776 | 3,03E-05 | 0,002585 | 145 |
| GO:0019866 organelle inner membrane | 3,54E-05 | 4,009657 | 3,54E-05 | 0,002968 | 259 |
| GO:0006281 DNA repair | 3,89E-05 | 3,984296 | 3,89E-05 | 0,003201 | 286 |
| GO:0009201 ribonucleoside triphosphate biosynthetic process | 4,36E-05 | 4,031523 | 4,36E-05 | 0,003526 | 79 |
| GO:0006259 DNA metabolic process | 4,57E-05 | 3,931776 | 4,57E-05 | 0,003627 | 460 |
| GO:0005743 mitochondrial inner membrane | 4,76E-05 | 3,941233 | 4,76E-05 | 0,003712 | 232 |
| GO:0045214 sarcomere organization | 5,02E-05 | 4,062879 | 5,02E-05 | 0,003849 | 57 |
| GO:0044429 mitochondrial part | 5,14E-05 | 3,901409 | 5,14E-05 | 0,003879 | 475 |
| GO:0009145 purine nucleoside triphosphate biosynthetic process | 5,54E-05 | 3,984612 | 5,54E-05 | 0,004049 | 70 |
| GO:0009206 purine ribonucleoside triphosphate biosynthetic process | 5,54E-05 | 3,984612 | 5,54E-05 | 0,004049 | 70 |
| GO:0022625 cytosolic large ribosomal subunit | 5,81E-05 | 4,160117 | 5,81E-05 | 0,004184 | 47 |
| GO:0044451 nucleoplasm part | 6,86E-05 | 3,834049 | 6,86E-05 | 0,004862 | 413 |
| GO:0051321 meiotic cell cycle | 7,82E-05 | 3,862158 | 7,82E-05 | 0,005438 | 101 |
| GO:0031033 myosin filament organization | 8,15E-05 | 4,084641 | 8,15E-05 | 0,005438 | 28 |
| GO:0031034 myosin filament assembly | 8,15E-05 | 4,084641 | 8,15E-05 | 0,005438 | 28 |
| GO:0071688 striated muscle myosin thick filament assembly | 8,15E-05 | 4,084641 | 8,15E-05 | 0,005438 | 28 |
| GO:0015935 small ribosomal subunit | 8,86E-05 | 3,954587 | 8,86E-05 | 0,00577 | 59 |
| GO:0009259 ribonucleotide metabolic process | 8,9E-05 | 3,775155 | 8,9E-05 | 0,00577 | 267 |
| GO:0019693 ribose phosphate metabolic process | 9,03E-05 | 3,770041 | 9,03E-05 | 0,005778 | 279 |
| GO:0015078 proton transmembrane transporter activity | 9,44E-05 | 3,796702 | 9,44E-05 | 0,005957 | 113 |
| GO:0009142 nucleoside triphosphate biosynthetic process | 0,000114 | 3,770568 | 0,000114 | 0,007079 | 85 |
| GO:0031672 A band | 0,000116 | 3,917425 | 0,000116 | 0,0071 | 35 |
| GO:0051726 regulation of cell cycle | 0,000119 | 3,692054 | 0,000119 | 0,007231 | 412 |
| GO:0009150 purine ribonucleotide metabolic process | 0,000129 | 3,680693 | 0,000129 | 0,007709 | 252 |
| GO:0030240 skeletal muscle thin filament assembly | 0,000156 | 3,884542 | 0,000156 | 0,009192 | 28 |

| | | | | | |
|---|----------|----------|----------|----------|-----|
| GO:0030241 skeletal muscle myosin thick filament assembly | 0,000158 | 3,889877 | 0,000158 | 0,009192 | 27 |
| KEGG | | | | | |
| dre03010 Ribosome | 7,59E-10 | 6,444811 | 7,59E-10 | 1,15E-07 | 127 |
| dre00190 Oxidative phosphorylation | 3,70E-08 | 5,574204 | 3,70E-08 | 2,79E-06 | 134 |
| dre03040 Spliceosome | 0,000233 | 3,558233 | 0,000233 | 0,011711 | 131 |
| dre01200 Carbon metabolism | 0,000357 | 3,425732 | 0,000357 | 0,013459 | 131 |
| dre00010 Glycolysis / Gluconeogenesis | 0,001543 | 3,007828 | 0,001543 | 0,046611 | 76 |
| dre00983 Drug metabolism - other enzymes | 0,001959 | 2,941778 | 0,001959 | 0,049312 | 61 |
| Stress vs. Control downregulated | | | | | |
| GO | | | | | |
| GO:0004713 protein tyrosine kinase activity | 2,73E-07 | -5,14243 | 2,73E-07 | 0,001048 | 127 |
| GO:0043235 receptor complex | 4,55E-07 | -4,96885 | 4,55E-07 | 0,001048 | 269 |
| GO:0043207 response to external biotic stimulus | 5,94E-06 | -4,42465 | 5,94E-06 | 0,006837 | 256 |
| GO:0051707 response to other organism | 5,94E-06 | -4,42465 | 5,94E-06 | 0,006837 | 256 |
| GO:0009607 response to biotic stimulus | 8,13E-06 | -4,35321 | 8,13E-06 | 0,007487 | 259 |
| GO:0009615 response to virus | 1,29E-05 | -4,36962 | 1,29E-05 | 0,009014 | 67 |
| GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway | 1,37E-05 | -4,22875 | 1,37E-05 | 0,009014 | 284 |
| GO:0019199 transmembrane receptor protein kinase activity | 1,73E-05 | -4,24773 | 1,73E-05 | 0,009953 | 91 |
| KEGG | | | | | |
| dre04010 MAPK signaling pathway | 4,24E-07 | -4,96907 | 4,24E-07 | 6,4E-05 | 349 |
| dre04621 NOD-like receptor signaling pathway | 0,000148 | -3,66037 | 0,000148 | 0,011205 | 154 |
| dre04620 Toll-like receptor signaling pathway | 0,00026 | -3,53213 | 0,00026 | 0,013066 | 95 |
| dre04744 Phototransduction | 0,000359 | -3,56559 | 0,000359 | 0,013567 | 36 |
| Fluoxetine vs. Control upregulated | | | | | |
| GO | | | | | |
| GO:0030017 sarcomere | 1,17E-07 | 5,333424 | 1,17E-07 | 0,000226 | 131 |
| GO:0044449 contractile fiber part | 1,46E-07 | 5,285806 | 1,46E-07 | 0,000226 | 132 |
| GO:0030016 myofibril | 1,62E-07 | 5,263313 | 1,62E-07 | 0,000226 | 133 |
| GO:0043292 contractile fiber | 2,02E-07 | 5,216665 | 2,02E-07 | 0,000226 | 134 |
| GO:0009144 purine nucleoside triphosphate metabolic process | 3,38E-07 | 5,092253 | 3,38E-07 | 0,000226 | 136 |
| GO:0009199 ribonucleoside triphosphate metabolic process | 3,69E-07 | 5,068422 | 3,69E-07 | 0,000226 | 143 |
| GO:0009205 purine ribonucleoside triphosphate metabolic process | 3,98E-07 | 5,059764 | 3,98E-07 | 0,000226 | 134 |
| GO:0006163 purine nucleotide metabolic process | 4,31E-07 | 4,981415 | 4,31E-07 | 0,000226 | 262 |
| GO:0019693 ribose phosphate metabolic process | 4,87E-07 | 4,953079 | 4,87E-07 | 0,000226 | 279 |
| GO:0009259 ribonucleotide metabolic process | 6,79E-07 | 4,887383 | 6,79E-07 | 0,000226 | 267 |
| GO:0006936 muscle contraction | 6,9E-07 | 4,97093 | 6,9E-07 | 0,000226 | 117 |
| GO:0009126 purine nucleoside monophosphate metabolic process | 7,34E-07 | 4,919859 | 7,34E-07 | 0,000226 | 145 |
| GO:0009167 purine ribonucleoside monophosphate metabolic process | 7,34E-07 | 4,919859 | 7,34E-07 | 0,000226 | 145 |
| GO:0006091 generation of precursor metabolites and energy | 7,39E-07 | 4,901995 | 7,39E-07 | 0,000226 | 176 |
| GO:0009150 purine ribonucleotide metabolic process | 8,2E-07 | 4,851689 | 8,2E-07 | 0,000226 | 252 |
| GO:0005865 striated muscle thin filament | 8,7E-07 | 5,11086 | 8,7E-07 | 0,000226 | 54 |
| GO:0036379 myofilament | 8,7E-07 | 5,11086 | 8,7E-07 | 0,000226 | 54 |
| GO:0009123 nucleoside monophosphate metabolic process | 8,83E-07 | 4,870419 | 8,83E-07 | 0,000226 | 162 |
| GO:0034660 ncRNA metabolic process | 1,16E-06 | 4,777442 | 1,16E-06 | 0,000276 | 332 |
| GO:0003012 muscle system process | 1,2E-06 | 4,8407 | 1,2E-06 | 0,000276 | 124 |
| GO:0009161 ribonucleoside monophosphate metabolic process | 1,26E-06 | 4,796776 | 1,26E-06 | 0,000276 | 158 |

| | | | | | |
|---|----------|----------|----------|----------|-----|
| GO:0072521 purine-containing compound metabolic process | 1,32E-06 | 4,74342 | 1,32E-06 | 0,000276 | 298 |
| GO:0003735 structural constituent of ribosome | 2,25E-06 | 4,727254 | 2,25E-06 | 0,000451 | 152 |
| GO:0009117 nucleotide metabolic process | 2,67E-06 | 4,586984 | 2,67E-06 | 0,000513 | 346 |
| GO:0046034 ATP metabolic process | 3,03E-06 | 4,633455 | 3,03E-06 | 0,000558 | 117 |
| GO:0006753 nucleoside phosphate metabolic process | 3,6E-06 | 4,521899 | 3,6E-06 | 0,000638 | 350 |
| GO:0022613 ribonucleoprotein complex biogenesis | 3,79E-06 | 4,530983 | 3,79E-06 | 0,000647 | 308 |
| GO:0044391 ribosomal subunit | 4,1E-06 | 4,599033 | 4,1E-06 | 0,000675 | 142 |
| GO:0098798 mitochondrial protein complex | 4,92E-06 | 4,503932 | 4,92E-06 | 0,000781 | 198 |
| GO:0009141 nucleoside triphosphate metabolic process | 6,48E-06 | 4,434776 | 6,48E-06 | 0,000994 | 152 |
| GO:0044455 mitochondrial membrane part | 7,59E-06 | 4,415163 | 7,59E-06 | 0,001128 | 163 |
| GO:0003009 skeletal muscle contraction | 9,42E-06 | 4,776851 | 9,42E-06 | 0,00132 | 28 |
| GO:0006412 translation | 9,46E-06 | 4,309842 | 9,46E-06 | 0,00132 | 412 |
| GO:0050879 multicellular organismal movement | 1,18E-05 | 4,652965 | 1,18E-05 | 0,001554 | 31 |
| GO:0050881 musculoskeletal movement | 1,18E-05 | 4,652965 | 1,18E-05 | 0,001554 | 31 |
| GO:0055086 nucleobase-containing small molecule metabolic process | 1,3E-05 | 4,230349 | 1,3E-05 | 0,00166 | 415 |
| GO:0034470 ncRNA processing | 1,37E-05 | 4,245744 | 1,37E-05 | 0,001665 | 254 |
| GO:0006941 striated muscle contraction | 1,37E-05 | 4,431813 | 1,37E-05 | 0,001665 | 50 |
| GO:0007601 visual perception | 1,56E-05 | 4,238356 | 1,56E-05 | 0,001837 | 147 |
| GO:0005840 ribosome | 1,63E-05 | 4,228984 | 1,63E-05 | 0,001875 | 179 |
| GO:0043043 peptide biosynthetic process | 1,98E-05 | 4,138762 | 1,98E-05 | 0,002219 | 417 |
| GO:0015980 energy derivation by oxidation of organic compounds | 2,13E-05 | 4,185421 | 2,13E-05 | 0,00233 | 123 |
| GO:0050953 sensory perception of light stimulus | 2,46E-05 | 4,123614 | 2,46E-05 | 0,002636 | 154 |
| GO:0006518 peptide metabolic process | 2,53E-05 | 4,073881 | 2,53E-05 | 0,002644 | 491 |
| GO:0070469 respiratory chain | 3,16E-05 | 4,165479 | 3,16E-05 | 0,00323 | 75 |
| GO:0009127 purine nucleoside monophosphate biosynthetic process | 3,59E-05 | 4,07192 | 3,59E-05 | 0,003516 | 85 |
| GO:0009168 purine ribonucleoside monophosphate biosynthetic process | 3,59E-05 | 4,07192 | 3,59E-05 | 0,003516 | 85 |
| GO:0043604 amide biosynthetic process | 3,87E-05 | 3,973568 | 3,87E-05 | 0,003712 | 480 |
| GO:0009124 nucleoside monophosphate biosynthetic process | 4,47E-05 | 3,999043 | 4,47E-05 | 0,00415 | 101 |
| GO:0017144 drug metabolic process | 4,51E-05 | 3,938214 | 4,51E-05 | 0,00415 | 365 |
| GO:0042254 ribosome biogenesis | 5,55E-05 | 3,917606 | 5,55E-05 | 0,005014 | 205 |
| GO:0030018 Z disc | 5,89E-05 | 3,97508 | 5,89E-05 | 0,005215 | 74 |
| GO:0009156 ribonucleoside monophosphate biosynthetic process | 6,16E-05 | 3,919026 | 6,16E-05 | 0,005352 | 98 |
| GO:0006164 purine nucleotide biosynthetic process | 6,51E-05 | 3,874823 | 6,51E-05 | 0,005555 | 156 |
| GO:0098800 inner mitochondrial membrane protein complex | 6,72E-05 | 3,911589 | 6,72E-05 | 0,005629 | 109 |
| GO:0009260 ribonucleotide biosynthetic process | 7,46E-05 | 3,837522 | 7,46E-05 | 0,006137 | 164 |
| GO:0009152 purine ribonucleotide biosynthetic process | 7,62E-05 | 3,836548 | 7,62E-05 | 0,006157 | 150 |
| GO:0046390 ribose phosphate biosynthetic process | 7,93E-05 | 3,821061 | 7,93E-05 | 0,006297 | 167 |
| GO:0009201 ribonucleoside triphosphate biosynthetic process | 8,25E-05 | 3,861156 | 8,25E-05 | 0,006438 | 79 |
| GO:0009145 purine nucleoside triphosphate biosynthetic process | 9,11E-05 | 3,847039 | 9,11E-05 | 0,006879 | 70 |
| GO:0009206 purine ribonucleoside triphosphate biosynthetic process | 9,11E-05 | 3,847039 | 9,11E-05 | 0,006879 | 70 |
| GO:0098803 respiratory chain complex | 0,000107 | 3,854088 | 0,000107 | 0,007957 | 67 |
| GO:0019752 carboxylic acid metabolic process | 0,00011 | 3,708618 | 0,00011 | 0,008036 | 500 |
| GO:0045333 cellular respiration | 0,000127 | 3,752971 | 0,000127 | 0,009139 | 88 |
| GO:0005861 troponin complex | 0,000129 | 3,998797 | 0,000129 | 0,009139 | 25 |
| GO:0072522 purine-containing compound biosynthetic process | 0,000135 | 3,682199 | 0,000135 | 0,009406 | 168 |
| GO:0005746 mitochondrial respiratory chain | 0,000138 | 3,779315 | 0,000138 | 0,009497 | 66 |

| | | | | | |
|---|----------|----------|----------|----------|-----|
| KEGG | | | | | |
| dre00190 Oxidative phosphorylation | 2,52E-06 | 4,679714 | 2,52E-06 | 0,000198 | 134 |
| dre03010 Ribosome | 2,62E-06 | 4,725296 | 2,62E-06 | 0,000198 | 127 |
| dre04744 Phototransduction | 7,92E-05 | 4,016019 | 7,92E-05 | 0,003691 | 36 |
| dre01200 Carbon metabolism | 9,78E-05 | 3,779534 | 9,78E-05 | 0,003691 | 131 |
| dre00010 Glycolysis / Gluconeogenesis | 0,000833 | 3,202248 | 0,000833 | 0,025153 | 76 |
| dre03040 Spliceosome | 0,001156 | 3,088301 | 0,001156 | 0,029099 | 131 |
| Fluoxetine vs. Control downregulated | | | | | |
| GO | | | | | |
| GO:0006955 immune response | 7,61E-07 | -4,84991 | 7,61E-07 | 0,003505 | 423 |
| Fluoxetine vs. Stress upregulated | | | | | |
| GO | | | | | |
| GO:0007601 visual perception | 7,36E-08 | 5,440696 | 7,36E-08 | 0,000271 | 147 |
| GO:0050953 sensory perception of light stimulus | 1,18E-07 | 5,335551 | 1,18E-07 | 0,000271 | 154 |
| GO:0005261 cation channel activity | 4,77E-06 | 4,464657 | 4,77E-06 | 0,005886 | 313 |
| GO:0001653 peptide receptor activity | 5,11E-06 | 4,483654 | 5,11E-06 | 0,005886 | 162 |
| GO:0050877 nervous system process | 6,56E-06 | 4,388221 | 6,56E-06 | 0,005946 | 419 |
| GO:0005216 ion channel activity | 7,75E-06 | 4,347982 | 7,75E-06 | 0,005946 | 408 |
| KEGG | | | | | |
| dre04010 MAPK signaling pathway | 5,6E-08 | 5,362301 | 5,6E-08 | 8,45E-06 | 349 |
| dre04744 Phototransduction | 1,29E-05 | 4,710578 | 1,29E-05 | 0,000971 | 36 |
| Fluoxetine vs. Stress downregulated | | | | | |
| GO | | | | | |
| GO:0099080 supramolecular complex | 9,16E-07 | -4,80511 | 9,16E-07 | 0,001996 | 435 |
| GO:0099081 supramolecular polymer | 9,16E-07 | -4,80511 | 9,16E-07 | 0,001996 | 435 |
| GO:0099512 supramolecular fiber | 1,3E-06 | -4,73273 | 1,3E-06 | 0,001996 | 434 |
| GO:0044427 chromosomal part | 1,76E-06 | -4,66885 | 1,76E-06 | 0,002025 | 461 |
| GO:0005865 striated muscle thin filament | 3,46E-06 | -4,79302 | 3,46E-06 | 0,002657 | 54 |
| GO:0036379 myofilament | 3,46E-06 | -4,79302 | 3,46E-06 | 0,002657 | 54 |
| GO:0005861 troponin complex | 4,07E-06 | -5,14199 | 4,07E-06 | 0,002676 | 25 |
| GO:0043292 contractile fiber | 8,54E-06 | -4,39165 | 8,54E-06 | 0,004915 | 134 |
| GO:0030016 myofibril | 1,07E-05 | -4,33912 | 1,07E-05 | 0,005311 | 133 |
| GO:0007059 chromosome segregation | 1,18E-05 | -4,30405 | 1,18E-05 | 0,005311 | 151 |
| GO:0044449 contractile fiber part | 1,27E-05 | -4,29935 | 1,27E-05 | 0,005311 | 132 |
| GO:0003735 structural constituent of ribosome | 1,57E-05 | -4,26674 | 1,57E-05 | 0,005614 | 152 |
| GO:0030017 sarcomere | 1,58E-05 | -4,24659 | 1,58E-05 | 0,005614 | 131 |
| KEGG | | | | | |
| dre03010 Ribosome | 1,37E-05 | -4,32619 | 1,37E-05 | 0,002074 | 127 |

Supplementary Table S10. Statistical data for qualitative real-time polymerase chain reaction results of the last (fifth) week of CUS showing differential expression of selected four reference genes with significant expression differences detected previously by the RNA-seq. Data is analyzed and represented using the Pfaffl method. Post-hoc Dunn's test for pairwise comparisons for significant Kruskal-Wallis data (see also Figure 6 in the MS for visual representation).

| Group | Pfaffl Mean±SEM | KW test | P value | Dunn's test | |
|--------------|------------------------|----------------|-------------------|--------------------|-------------------|
| saga | | | | | |
| Control | 1.461±0.4057 | 8.302 | 0.0157 | C vs. S | 0.1344 |
| Stress | 0.6749±0.1122 | | | C vs. F | >0.9999 |
| Fluoxetine | 1.901±0.47 | | | S vs. F | 0.0156 |
| isg15 | | | | | |
| Control | 2.384±0.7881 | 21.6 | <0.0001 | C vs. S | <0.0001 |
| Stress | 0.0229±0.007507 | | | C vs. F | 0.0277 |
| Fluoxetine | 0.1818±0.06124 | | | S vs. F | 0.1264 |
| otx5 | | | | | |
| Control | 3.013±1.067 | 12.71 | 0.0017 | C vs. S | 0.0384 |
| Stress | 0.5811±0.2882 | | | C vs. F | >0.9999 |
| Fluoxetine | 3.904±1.102 | | | S vs. F | 0.0017 |
| tpm4 | | | | | |
| Control | 1.09±0.1964 | 7.804 | 0.0202 | C vs. S | 0.0183 |
| Stress | 2.325±0.4452 | | | C vs. F | >0.9999 |
| Fluoxetine | 1.37±0.1431 | | | S vs. F | 0.2023 |

Cited references:

- 1 Love, M. I., Anders, S. & Huber, W. (2019).
- 2 Wickham, H. *ggplot2: elegant graphics for data analysis*. (Springer, 2016).
- 3 Royer, L., Reimann, M., Andreopoulos, B. & Schroeder, M. Unraveling protein networks with power graph analysis. *PLoS Comput Biol* 4, e1000108 (2008).
- 4 Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D. & Woolf, P. J. GAGE: generally applicable gene set enrichment for pathway analysis. *BMC Bioinformatics* **10**, 161, doi:10.1186/1471-2105-10-161 (2009).